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INTRODUCTION: 
 
Discovery of the first Human Retrovirus: 
 
The closing of the 1970s ushered a new direction for tumor 
biology when Robert C. Gallo published the first report of a virus 
capable of causing a human leukemia (1).  Prior to this discovery, 
belief in a human tumor retrovirus was diminishing, as little evidence 
could be found bringing credence to the theory.  Retroviruses had 
been found in non-human primates capable of causing tumors, but 
evidence was still lacking in humans.  This changed when Gallo and 
colleagues, who were working on animal retroviruses that caused 
leukemia, were able to isolate a T-cell specific growth hormone (now 
known as interleukin-2, IL-2) which allowed growth of normal 
lymphocytes beyond the one week limit which was achieved when 
growing cells under phytohemagglutinin (PHA) stimulation (2, 3).  
In addition, the discovery, and subsequent purification, of a reverse 
transcriptase (RT) in 1970 (4,5) provided researchers with a powerful 
tool to identify retroviruses.  With these tools, in 1979, Gallo and 
colleagues isolated human T-cell leukemia virus-I (HTLV-I) from a 
T-cell line established from a patient, with, what was then described 
as a cutaneous T-cell lymphoma (6).   Around the same time, in 
1976, a group of Japanese scientists, led by Kiyoshi Takatsuki 
recognized a distinct geographical distribution of leukemia, which 
they termed adult T-cell leukemia (ATL), found in the southwestern 
region of Japan (7).  These patients later tested positive to antibodies 
to HTLV-I.  In 1981, it was agreed that HTLV-I was etiologically 
linked to ATL, and subsequently found to be endemic to particular 
regions of Japan, the Caribbean, South America, and Africa.  
Confirmation for a direct causative role for HTLV-I in ATLL, was 
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confirmed when it was discovered that proviral integration was 
nearly all due to clonal infection of leukemic cells, supporting the 
idea that HTLV-I was the cause of ATL (8).  Subsequent studies 
found HTLV-I to be the etiological agent of tropical spastic 
paraparesis (TSP) in Jamaica and HTLV-1-associated myelopathy 
(HAM) in Japan, later established as identical neurodegenerative 
diseases of the spinal cord (9,10).  Since these initial discoveries, 
HTLV-I has been implicated in some forms of HTLV-I-associated-
uveitis (HAU), HTLV-I-assoicated-arthropathy (HAAP), infective 
dermatitis, and polymyositis (11).   
Today it is estimated that 20-30 million people worldwide are 
infected with HTLV-I, with 1-5% afflicted with adult T-cell 
leukemia/lymphoma (ATLL) (12).  It is estimated that each year, 
over 700 cases of ATLL are diagnosed, and antibodies against 
HTLV-I are detected in over 1 million individuals, from Japan alone 
(13).  HTLV-I is endemic to Japan, Africa, South America, the 
Caribbean basin, southwestern portions of North America and 
Eastern Europe (14). 
ATLL is classified into several forms, including acute, 
chronic, smoldering, or lymphoma.  Approximately 75% of 
individuals with ATLL manifest with leukemia, the great majority of 
which are acute.  The remaining 25% have a pure lymphoma form, 
with no blood involvement (15).  The clinical forms of ATLL are 
based largely on the extent of systemic leukemia, organ involvement, 
and the extent of hypercalcaemia, with the acute and lymphoma 
forms generally having a worse prognosis.  The most common 
diagnostic parameters include the morphology of circulating 
lymphocytes, which take on a characteristic “flower cell” appearance 
due to the presence of polylobulated nuclei (Figure 1), along with 
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positive tests to HTLV-I serum antibodies and a distinct 
immunophenotype (15). 
 
Figure 1:  “Flower cell” nuclei in HTLV-I infected cell: 
 
  
 
The clinical prognosis of patients diagnosed with acute and 
lymphoma ATLL is extremely poor.  Acute ATLL is rapidly fatal, 
with a median survival time of 6 months with therapy.  Survival 
times for chronic and lymphoma type ATLL, are 24 and 10 months, 
respectively (16).  Survival times for smoldering ATLL are quite 
long, but can progress to an acute or lymphoma type ATLL.  Fatality 
is often ascribed to pulmonary complications, opportunistic 
infections, sepsis, and uncontrolled hypercalcaemia (14).  
HTLV-I is primarily spread by vertical transmission through 
breast feeding, but also occurs by parenteral, sexual, or blood 
transmission, whereby live infected T-lymphocytes are exchanged 
via milk, semen, or blood.  HTLV-I predominately infects CD4+ T-
lymphocytes, with minor infections seen in CD8+ T-lymphocytes, 
epithelial and endothelial cells, and astrocytes (in the case of 
TSP/HAM) (17).  Viral spread usually occurs by cell-to-cell contact, 
via viralogical synapses, and infection by fee virions is poor.  Upon 
entering the cell, the diploid RNA genome of HTLV-I is reverse 
transcribed into DNA, whereupon the provirus integrates randomly 
into the host genome.  HTLV-I multiplication, however, depends 
DAPI stain of an HTLV-I 
infected cell, demonstrating 
the characteristic, 
polylobutlated nuclei. 
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upon the enhancement of proviral-infected cells, and the processes of 
reverse transcription/integration are usually brief, occurring only 
during initial infection by new virions (14).  Clonal expansion of 
infected cells is mainly attributed to viral spread.   
The HTLV-I genome consists of the gag, pol, and env genes, 
along with the 5’ and 3’ long terminal repeats (LTRs) (Figure 2).   
gag encodes for the viral matrix, capsid and nucleocapsid, pol 
encodes for the viral reverse transcriptase, integrase, and protease 
and env encodes for the envelope protein (7).  Between the env gene 
and the 5’-LTR, is a unique pX region.  This region encodes for the 
viral regulatory and accessory proteins, tax, rex, p12, p13, p30, and 
p21, which are encoded through alternatively splicing (Figure 2).   
 
Figure 2:  HTLV-I genome and the expression of unique proteins 
(Adapted from (8)):  The unique accessory proteins (green) encoded 
in the pX region of HTLV, include tax, rex, p30, p12, p13, and HBZ.  
The cellular localization of tax, rex, p30, p12, and p13 is represented 
with green fluorescence on the left.   The splicing patterns for the 
unique proteins are indicated below. 
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Expression of the main viral transactivator protein, Tax, 
increases viral and cellular transcription by enhancing transcription 
from the viral 5’-LTR and increasing the activities of key cellular 
transcriptional regulators, such as NF-κB, serum response factor 
(SRF), activated protein 1 (AP-1), cyclic AMP response element-
binding protein (CREB) and CREB binding protein (CBP) (19).  Rex 
suppresses splicing of HTLV-I transcripts, decreasing viral gene 
expression by negatively regulating Tax, and instead favoring 
expression of viral structural proteins (20).  p12 increases viral 
infectivity by increasing nuclear factor of activated T-cells (NFAT) 
expression and affecting janus-associated kinases (JAKs) signaling, 
leading to signal transducer and activator of transcription-5 (STAT5) 
transcriptional activities.  p12 also has a role in HTLV-I avoidance of 
host cellular immunity by retranslocting major histocombatability 
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complex I (MHC I) to the cytosol where it is degraded (21).   p30 
allows for establishment and long-term maintenance of proviral-
infected cells by selectively retaining the tax/rex message in the 
nucleus (22).  By inhibiting Tax/Rex protein expression, p30 
effectively “silences” HTLV-I, allowing for the persistence of cells 
containing the proviral genome.  Recently, the minus strand of 
HTLV-I has been found to encode for the HTLV-I b-ZIP factor 
(HBZ), which has dual roles in enhancing or suppressing HTLV-I 
proliferation (23).   
 
HTLV-I Viral Transformation: 
 
 HTLV-I infection is characterized by enhanced viral 
expression during early stages of disease, with little, to no viral gene 
expression as the disease progresses.  In fact, over 95% of ATLL cell 
in vivo are negative for HTLV-I expression (24).  Despite this fact, 
integrated proviral DNA can readily be detected and culturing of 
ATLL cells ex vivo leads to immediate expression of viral genes.  
Studies have shown that a single HTLV-I clone can persist in an 
infected individual for over 7 years (25,26).  This suggests that the 
proviral genome remains intact and is suppressed during latency.  
Current models of the HTLV-I life cycle, propose that the initial 
infection of T-cells leads to proviral integration, followed by 
expression of key viral proteins (ie. Tax), which promote cellular 
proliferation in absence of apoptosis and cellular senescence (Figure 
3).  Tax initiates viral transformation; yet viral expression is 
tempered by the expression of HTLV-I encoded negative regulators, 
allowing the proviral-harboring cell to persist.   With barely 
detectable levels of viral gene expression, and without the need for 
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the production of free virions to replicate, HTLV-I provides an 
environment whereby cells can expand in absence of detection by 
host immune surveillance mechanisms.  Enhanced proliferation of 
infected cells over a long latency period leads to genetic alterations 
and mutations, which drive the creation of a malignant phenotype.  
This model is supported by ATLL disease progression, in which 
ATLL requires 20-30 years after initial HTLV-I infection to develop.   
 
Figure 3:  Model of HTLV-I-mediated cellular transformation.  
Initial HTLV-I infection is characterized by high expression of the 
tax protein, which may promote genetic instability during early 
infection.  Over a long latency period, of approximately 20-30 years, 
ATLL develops in absence of viral protein expression. 
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 HTLV-I-mediated T-cell transformation is largely carried out 
by over-expressing cellular genes involved in normal T-cell growth 
and survival and deregulating cellular genes involved in cell cycle 
 12 
 
control and DNA damage repair.  As stated above, viral 
transformation, at least in the early stages of disease, is mainly 
carried out by Tax (27).  Tax has been shown to immortalize T-cells 
and transform fibroblasts in vitro, and produce tumors in transgenic 
mice (28-32).      
Expression of Tax leads to up-regulation of several cytokine 
receptors.  Some of their targets, such as, phosphoinositide kinase-
3(PI3K)/AKT, and extracellular signal-regulated kinase (ERK)/Jun 
N-terminal kinase (JNK), are activated in HTLV-I infected cells and 
contribute to transformation (33,34).  Also, transforming growth 
factor-β (TGF-β) is inactivated in HTLV-I infected cells (35).  
Arguably the most vital of cytokine receptors in Tax-mediated 
cellular transformation is the IL-2Rα chain (36, 37).  Expression of 
the IL-2Rα chain allows signaling at low concentrations of IL-2, 
through a complex consisting of IL-2Rβ and γ.  Independence of IL-2 
is an established characteristic of HTLV-I transformed cells, whereas 
HTLV-I infected cells that require exogenous IL-2 are considered 
immortalized.  Though expression of Tax can lead to activation of 
the IL-2 promoter, IL-2 mRNA and protein are not detected in 
HTLV-I infected cells.  This, along with the fact that HTLV-I 
immortalized cell lines are IL-2 dependent, suggests that an IL-2 
autocrine loop does not contribute to HTLV-I-mediated 
transformation.   Instead, HTLV-I infected cell lines and ATLL cells 
demonstrate constitutive activation of the JAK/STAT pathways, with 
constitutive tyrosine phosphorylation of JAK3 and STAT5 (38-41).  
In addition to Tax, p12 can also stimulate IL-2 production and 
activation of the JAK/STAT pathway (42).  
Another characteristic of HTLV-I transformed cells is their 
constitutive activation of the NF-κB pathway (36, 37, 43-45).   NF-
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κB promotes cellular growth and survival, and suppresses proteins 
involved in cell cycle regulation and DNA repair (46).  Studies have 
shown that NF-κB is essential for IL-2 independent, Tax-induced 
growth of T-cells (47).  Though the exact mechanism of NF-κB 
activation is not known in ATLL patients, in HTLV-I cells lines, it 
likely involves deregulation of several aspects of the NF-κB pathway 
by Tax (46).  Expression of Tax leads to phosphorylation and 
degradation of IκBα and β, negative regulators of NF-κB (48-52).  
Degradation of IκB is due in part, to Tax stimulation of IκB kinase 
complexes (IKKs) (53-55).  Tax has also been shown to bind IKKγ, 
the docking subunit of the IKK complex, thus allowing IKK to 
become constitutively active.   
HTLV-I enhances proliferation in infected cells by altering 
cell cycle regulation and inhibiting apoptosis.  Expression of the anti-
apoptotic regulators, Bcl-xL and Bcl-2  are enhanced in HTLV-I 
infected cells, as well as the Bcl-2 related protein A1 (Bfl-1) and 
human inhibitor of apoptosis (HIAP-1)/cellular inhibitor of apoptosis 
2 (CIAP-2) (56-58).  In addition, activation of AKT, in HTLV-I 
infected cells, leads to phophorylation of Bad, an inhibitor of Bcl-xL 
and activation of NF-κB, leading to increased expression of Bcl-xL 
(59).  Expression of Tax has also lead to inhibition of the caspase 
cascade (60), increases in the expression of survivin in ATLL cells 
and HTLV-I cell lines (61,62), inhibition Fas-mediated apoptosis, 
and aiding in the resistance to Apo2ligand/TRAIL-mediated 
apoptosis (63-65). 
p53 is a tumor suppressor which guards the genome by 
arresting cells in the G1/S phase of the cell cycle, in order to repair 
damaged DNA.  Around 50% of all cancers show mutations in p53; 
however, the majority of HTLV-I infected cells have wild-type p53, 
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with only 25% carrying p53 mutations (66, 67).  Despite stable p53 
expression, p53 is transcriptionally inactive in the majority of HTLV-
I infected cells.  It is currently unclear whether p53 activity is 
inhibited by competition with CBP/p300, perturbations in the NF-κB 
pathway, and/or a novel, undefined mechanism (68).  In addition to 
inactivating p53, HTLV-I infected cells also inactivate the tumor 
suppressor, retinoblastoma protein (Rb), which negatively regulates 
cell cycle progression (69).  Tax expression leads to 
hyperphosphorylation of Rb - thereby releasing the transcription 
factor, E2F, which can further activate various cyclins, cyclin-
dependent kinases (cdks), and proliferating cell nuclear antigen 
(PCNA), which promote cell cycle progression.   Tax has also been 
shown to bind Rb directly and cause its degradation (69).  Tax has 
pleitropic effects on cell cycle regulators, with the general effect to 
promote cellular proliferation. Tax increases the expression of 
cyclins (ie. cyclin D2), cdks (ie. cdk4 and 6) (70) and the anti-
apoptotic cyclin kinase inhibitor (CKI), p21WAF/CIP1 (71-73). Tax can 
also negatively regulate other CKIs (p15INK4b, p16INK4a, p18INK4c, 
p19INK4d, p27KIP1) (74-77).  In addition to these Tax-mediated effects, 
acute ATLL patient’s samples often demonstrate deletions in 
p16INK4a and p15INK4b (78,79).  In contrast, HTLV-I cell lines 
demonstrate hypermethylation of the p16INK4a promoter (79).   
 HTLV-I infected cells are predisposed to somatic mutations 
and chromosome instability, and often have severe cytogentic defects 
(16,80).  In fact, 96% of ATLL cases demonstrate clonal 
chromosomal abnormalities (Kamada A, 1992).  Aneuploidy and 
chromosome breaks are frequent in ATLL patients, with no specific 
karyotype abnormality (80,11).  Faulty chromosome transmission 
and failures in cytokinesis occur.  This suggests severe impairments 
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in mitosis.  Tax leads to early activation of the anaphase promoting 
complex (APC), prior to initiation of mitosis that leads to 
deficiencies in the functions of securin and cyclin B1 (81,82).  
HTLV-I infected cells also target the functions of centrosomes, and 
demonstrate centrosome amplification and micronuclei formation 
(83).  HTLV-I infection may also lead to genetic instability by 
repressing DNA repair mechanisms.  Studies have shown that the 
most affected DNA repair pathway by Tax overexpresion is the base 
excision repair pathway (BER) (84).  HTLV-I infected cells repress 
DNA polymerase β, which leads to impairments in BER of DNA (84, 
85).   Nucleotide excision repair (NER) is also repressed in HTLV-I 
infected cells through Tax activation of PCNA and p53 dysfunction 
(86-88). In addition, interferon regulatory factor 4 (IRF-4) is 
constitutively actived in HTLV-I infected cells, and causes a 
reduction in mitotic and DNA repair genes, including cyclin B1 and 
Rad51 (89, 90).   
Despite Tax’s pleitropic roles in promoting cellular 
transformation, Tax is barely detectable in leukemic cells (24, 91), 
implying that Tax expression is not required to maintain the 
transformed phenotype.  However, Tax can be detected in 
seropositive carriers, suggesting it has a more important role in 
initiating cellular events.  During the long latency period that follows 
infection, the accumulation of genetic mutations and the appearance 
of a “tax phenotype”, in absence of Tax expression, are expected to 
drive in vivo cellular transformation, yet little is known regarding the 
transition from a Tax-dependent phenotype to a Tax-independent 
phenotype (16).  The process is believed to involve multiple genetic 
and epigenetic events that promote leukemogenesis and ATLL.   
According to the cancer theory, a characteristic set of molecular and 
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cellular alterations are required in order to obtain and maintain a 
malignant phenotype.  Some studies report at least 5 genetic or 
epigenetic events must be acquired for leukemogenesis (92).  In 
absence of Tax, somatic mutations and chromosomal instability may 
provide genetic “hits” that allow an infected cell to proliferate 
indefinitely.  We have found that one of these genetic hits is the 
reactivation of telomerase.      
 
Telomeres and Telomerase: 
 
 Prior to the discovery of the structure of DNA, Barbara 
McClintock and Hermann Muller realized that chromosomes had 
unique ends, which they termed telomeres (93).  Subsequently, 
researchers discovered that somatic cells had a finite proliferative 
capacity due to the “end replication problem”:  DNA synthesis leads 
to a progressive shortening of DNA termini after successive cellular 
divisions.  This is due to the fact that DNA can only be synthesized 
in the 5’-3’ direction.  To overcome this problem, lagging strand 
DNA synthesis requires the addition of small RNA oligonucleotides 
that are used as primers for DNA polymerase.  However, removal of 
the RNA primer from the terminal end of chromosomal DNA, leads 
to incomplete DNA replication, with a loss of 50-200 nucleotides, 
which cannot be replicated (94).  Through successive replication 
cycles, this would eventually lead to shortening of DNA, with the 
possibility of degradation of vital, gene-encoding sequences (Figure 
4). 
 
Figure 4:  The End Replication Problem (Adapted from(95)).   The 
end replication problem occurs during normal DNA replication, in 
which there is incomplete DNA synthesis of the lagging strand.  This 
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leads to a loss of DNA after every replication cycle.  Telomerase can 
extend the ends of chromosomes by synthesizing telomere repeats 
(circles) onto the DNA termini. 
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In 1985, Elizabeth Blackburn and colleges discovered that a 
cellular enzyme, telomerase, could extend the ends of chromosomal 
DNA by synthesizing repetitive tracts (TTAGGG) of DNA (96).   
These tandem arrays, or telomeres, which reached an average length 
of 12 kb in somatic cells, could solve the “end replication” problem.   
 Telomerase is a ribonucleotide complex, composed of an 
RNA component (hTR) that partially serves as a template for the 
synthesis of the six base-pair repeat that is added onto chromosome 
ends (97).  This action requires a reverse transcriptase component, 
hTERT that uses hTR as a template for synthesizing DNA (96, 98, 
99).  Additional proteins have been discovered that aid in telomerase 
activity, along with the assembly and maturation of the telomerase 
complex (100).  In addition, telomeric DNA is bound by various 
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components of the shelterin complex, which can alter the state of the 
telomere and protect chromosome ends from fusion and recognition 
as DNA double-stranded breaks (101) (Figure 5).  Shelterin is 
composed of the TTAGG-repeat binding factors – 1 and -2 (TRF1 
and TRF2), their binding partners, TRF1-interacting nuclear protein 
2 (TIN2) and hRAP1, along with protection of telomeres (POT1) and 
its regulator, POT1- and TIN2-interacting protein (PTOP).  Shelterin 
determines the structure of the telomere ends, generates the t-loop (a 
possible protection mechanism against non-homologous end joining 
(NHEJ) repair, whereby the single-stranded 3’-end of telomeres 
invades the double-stranded telomeric DNA), and controls 
telomerase synthesis of telomeres, by blocking telomerase access to 
telomere ends (101, 102).  Telomere attrition or inhibition of TRF2, 
TIN2, or POT1 results in unprotected telomeric sequences and 
activation of DNA damage response factors (101, 103, 104).  ATM 
or ATR kinases are activated leading to p53-dependent G1/S cell 
cycle arrest, eventually ending in apoptosis or senescence.  In p53-
deficient cells, telomere dysfunction leads to p16 induction and 
proliferation inhibition (105). 
 
Figure 5:  Shelterin bound to Telomeres (Adapted from (106)): A 
model of telomere ends.  Telomeres are bound by various complexes 
of shelterin, composed of the DNA binding proteins, TRF1 (purple), 
TRF2 (Blue), and POT-1 (Yellow), and their binding partners, TIN2 
(light blue), hRAP1 (Brown), and PTOP (Green).  Shelterin can aid 
in the formation of the t-loop, which may protect telomere ends.   
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 Telomerase is regulated through alternative splicing, 
epigenetic modifications, and both transcriptional and post-
transcriptional control.  Alternative splicing leads to the presence of 
multiple hTERT transcripts carrying deletions of critical motifs 
required for reverse transcription (107).  Post-transcriptional control 
occurs through several mechanisms.  AKT and RelA/p65 can lead to 
nuclear translocation of hTERT, the former, by phosphorylation of 
hTERT, the latter by direct binding (108,109).  PKC can also 
phosphorylate hTERT resulting in interactions with hsp90 that have a 
role in hTERT holoenzyme integrity (110).  Alternatively, 
phosphatase 2A (PP2A) can negatively regulate hTERT through 
dephosphorylation (111).  Despite these regulatory mechanisms, 
telomerase is primarily regulated at the level of transcription (Figure 
6).   
 
Figure 6:  Select positive and negative regulators of hTERT 
transcription.  The hTERT promoter consists of the proximal and 
distal regions, which are bound by transcription factors.  Sp1/Sp3 and 
c-Myc are positive regulators, whereas, WT1 is a negative regulator.  
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Members of the AP-1 transcription family (c-fos, c-Jun, and JunD) 
bind to the distal promoter and are positive and negative regulators of 
hTERT expression.   
 
Distal Promoter Proximal Promoter
c‐fos/c‐Jun
c‐fos/JunD
SP1
SP3
WT1
‐ + + ++++/‐ +/‐
hTERT
+/‐
 
 
 
 
Several E-box and GC-rich elements are present in the hTERT 
promoter that bind c-Myc and Sp1, respectively (112).  These 
transcription factors have been shown to be strong positive regulators 
of hTERT expression.  Other positive regulators include survivin and 
estrogen (113, 114).  Known negative regulators are Wilm’s tumor 
protein (WT1), p53, p16INK4A, smad3, and p27KIP1 (115-118). A 
positive and negative role on hTERT transcription for the AP-1 
transcription factors, E2F-transcription factor (E2F-1), and upstream 
stimulatory factor (USF-1/2) has also been shown (119, 120). 
 
Telomerase and Cancer: 
 
 Telomere length is either maintained at a steady-state length 
or is lengthened or shortened depending on the level of telomerase 
and/or the state of the telomere (100).  The effects of either a loss or 
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gain of telomerase function is implicated in the processes of aging 
and cancer, respectively (Figure 7).    
 
Figure 7:  Change overtime in Telomere Length in Normal and 
Carcinogenic Cells (121)).  Normal human cells start with 
approximately 12kb of telomeres, which are gradually lost during 
normal DNA replication over the life of the individual.  Eventually 
this leads to either apoptosis or senescence when the telomeres reach 
a critical length.  Cancer cells circumvent this problem, by increasing 
the activity of telomerase, which can extend the lifetime of a cell. 
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hTERT is expressed in transformed cells, but not in primary 
somatic cells in culture (100).  In fact, 90% of all cancers over 
express telomerase, with the additional 10% relying on an alternative 
lengthening of telomeres (ALT) pathway to maintain telomere length 
(122, 123).  Despite the strong association between telomerase and 
carcinogenesis, a direct role for telomerase in causing cellular 
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transformation is unlikely.  Telomerase is able to enhance the 
replication span in somatic cells; however, the cells do not form 
tumors in mice, nor colonies in soft agar assays (124).  When 
telomerase is overexpressed with either the large T-antigen of simian 
virus 40 (SV40) and Ras, or when Rb and p53 are inactivated along 
with expression of Ras and c-Myc, normal human cells can become 
transformed (125, 126).  A direct correlation between telomere 
length and replicative senescence is clear.  Normal cells expressing 
telomerase, maintain telomere lengths and show indefinite cellular 
proliferation (127).      
 The majority of cancer cells demonstrate high telomerase 
activity with short telomeres (128, 129, 120).  A study has shown 
that the level of telomerase activity mainly depends on the number of 
tumor cells present, whereby hTERT is detected in nearly all cells in 
cancers with high telomerase activity, and in fewer cells where 
telomerase activity is low (130).     
 
HTLV-I and Telomerase: 
 
 Elevated telomerase activity is seen in all ATLL patients, 
including smoldering, chronic, and acute ATLL (131).  Initial studies 
found that telomerase activity, correlated with disease status, in that 
acute and chronic ATLL patients demonstrated higher telomerase 
activity than asymptomatic carriers.   
 We were the first lab to demonstrate a direct role for HTLV-I 
in increasing telomerase expression and activity (Figure 8) (132).  
Co-culturing of PBMCs with a gamma-irradiated HTLV-I producing 
cell line (MT2), led to increases in telomerase expression and 
activity.  These in vitro results were confirmed in vivo, as real-time 
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PCR analysis demonstrated that ATLL patient samples had elevated 
hTERT expression compared to normal PBMCs.  We further showed 
that Tax-mediated NF-κB activation was able to increase hTERT 
expression by increasing the binding of c-Myc and Sp1 to the hTERT 
promoter. 
 
Figure 8:  Increased telomerase expression and activity in HTLV-I 
cells and ATLL patients.  Real-Time quantitative PCR of hTERT 
expression in normal PBMCs co-cultivated with gamma-irradiated 
MT2 (HTLV-I producing cell line) cells over time.  After 12 weeks 
of cultivation, the cells became immortalized (MU04).  TRAP assay 
of telomerase activity in normal PBMCs, MT2, and MU04 cells.  
TPGs are indicated below.  Real-Time quantitative PCR of hTERT 
expression in HTLV-I, negative donors, asymptomatic patients, and 
ATLL patients.   
 
 
 
 
 
 The following studies continue the evaluation of telomerase 
and telomeres in HTLV-I infected cells.  We demonstrate that 
telomerase activity is increased in HTLV-I infected cells and ATLL 
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patient samples, and that this increase is accompanied by a 
progressive shortening of telomere lengths (133).  However, telomere 
lengths are stabilized, and HTLV-I infected cells are prevented from 
entering cellular senescence and apoptosis, by an increase in shelterin 
components, including TRF1, TRF2, and TIN2.   Continuing the 
study of telomerase regulation in HTLV-I cells, we find that the IL-
2R signaling pathway is vital in promoting strong telomerase activity 
(Bellon M and Nicot C, Submitted).  IL-2R signaling leads to PI3K 
activation, which allows for cytoplasmic retention of the telomerase 
inhibitor, WT1.        
 Finally, we demonstrate that inhibition of telomerase activity 
leads to cellular senescence in HTLV-I infected cells and ATLL 
patient samples (134).  We find that treatment with AZT 
(zidovudine), can lead to complete or partial remission of ATLL 
patients that carry a functional p53.   
 The data presented herein, clearly demonstrate a strong 
association between HTLV-I infection and telomerase activity.  
Similar to all oncogenic viruses, telomerase is required to maintain 
long-term proliferation and tumorgenesis during HTLV-I disease 
progression.   
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Increased Expression of Telomere Length 
Regulating Factors TRF1, TRF2 and TIN2 in 
Patients with Adult T-Cell Leukemia 
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Increased Expression of Telomere Length Regulating 
Factors TRF1, TRF2 and TIN2 in Patients with Adult 
T-Cell Leukemia. 
 
ABSTRACT:  
Here, we report that freshly isolated unstimulated adult T-cell 
leukemia (ATL) cells present high telomerase activity compared to 
asymptomatic carriers or normal donors. In spite of this high 
telomerase activity, ATL cells retained shorter telomeres compared 
to those of uninfected cells isolated from the same patients. Because 
the safeguarding of telomere length is critical to the unlimited 
proliferation of tumor cells, we investigated the underlying 
mechanism for short telomere maintenance in ATL cells.  
Transcriptional and post transcriptional expression of telomere 
binding proteins TRF1, TRF2, TIN2 and POT1, known to regulate 
telomere homeostasis and protection, were evaluated. We found that 
TRF1 and TRF2 are over-expressed in in vivo patient’s samples from 
ATL but not asymptomatic carriers while levels of POT1 expression 
did not specifically increase in ATL.  To gain insights into the 
regulation of TRF genes in HTLV-I infected cells we investigated the 
expression of TIN2, a regulator of these genes, and found an increase 
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in TIN2 expression in ATL patients. Together our results underscore 
the importance of telomerase and telomere length regulating factors 
as novel markers for ATL disease progression and as potential 
therapeutic targets for the treatment of HTLV-I-associated 
malignancies. 
 
INTRODUCTION:  
 
Human T-cell leukemia virus type 1 (HTLV-I) is the etiological 
agent of adult T-cell leukemia/ lymphoma (ATL), an aggressive and 
fatal lymphoproliferative disorder (1,2). The poor prognosis of ATL 
patients is associated with the resistance of neoplastic cells to the 
conventional combination of high-dose chemotherapy and 
radiotherapy (3). The mechanism by which HTLV-I engenders ATL 
is not clear, but the long latency period of several decades preceding 
the disease suggests it relies upon long term survival and 
proliferation of virus-infected cells (4-6). In fact, previous studies 
have shown that proliferation of ATL cells occurs mainly by 
replication of infected cells leading to oligoclonal or monoclonal 
expansion (4-6). HTLV-I has evolved regulatory mechanisms to 
usurp cell cycle checkpoints (7-12) and apoptosis regulators (13-17), 
and infected cells may escape from immune defenses using a 
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combinatorial effect of the regulatory proteins p30 and p12 that 
reduce viral expression and down-regulate major histocompatibility 
complex (MHC) expression, respectively (18-19). 
 The DNA polymerase is unable to replicate telomeric 
structures, and thus each cellular division results in a progressive 
shortening of the telomere length. While telomere shortening may be 
associated with increased chromosomal instability and may facilitate 
carcinogenesis, it can also lead to irreversible senescence. Although 
in most cancer cells avoidance of telomere shortening beyond a 
critical size requires reactivation of telomerase expression, the sole 
expression of telomerase may not be sufficient for telomere 
elongation due to the “open or closed” nature of the telomeric ends, 
which controls accessibility of telomerase to the telomeres(20). The 
nature of the telomeric ends is governed by the binding of TTAGGG 
repeat binding factors, TRF1 and TRF2, which act as negative 
regulators of telomere length (21-23), and of the protection of 
telomere, POT1, which binds to the single-stranded TTAGGG 
repeats of telomeres, protecting the ends of chromosomes and 
relaying signals of telomere length through its binding with TRF1 
(24,25).  Studies have shown that enforced over-expression of TRF1 
or TRF2 leads to rapid telomere shortening while prolonged over-
expression of TRF1 is associated with the maintenance of stable, 
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short telomeres. Many other factors involved in the regulation of 
telomere length have been identified, including the TRF1-interacting 
nuclear protein 2, TIN2, which can interact with both TRF1 and 
TRF2, and indirectly influence telomere length (26).  In tumor cells, a 
dynamic equilibrium exists in the relative expression of these factors 
in order to maintain the telomere length and endure unlimited cellular 
proliferation.  
 Here we report that in vivo HTLV-I-infected ATL patient’s 
samples have high telomerase activity as evidenced by TRAP assay. 
Despite this finding we found that telomere lengths were 
significantly shorter in ATL cells when compared to non-infected 
cells isolated from the same patients. Analysis of telomere binding 
factors showed no specific alteration in the expression of POT1. 
However, we found a significant increase in TRF1, TRF2 and TIN2 
gene expression in ATL patients compared to asymptomatic carriers. 
These results were further confirmed at the protein level, suggesting 
that these factors represent novel makers for ATL and may play a 
role in disease progression. TRF1, TRF2, and TIN2 have been shown 
to inhibit apoptosis and DNA damage response cell cycle arrest and 
may contribute to the proliferation of ATL cells despite telomere 
attrition. The presence of shorter telomeres in ATL cells compared to 
normal cells and the elevated expression of TRF1 and TIN2 support 
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the concept that telomeric binding proteins may be used as 
therapeutic targets and warrant future investigations.  
RESULTS: 
 
 We and others have reported that HTLV-I infection increased 
hTERT mRNA expression 27-(27-31), in part through activation of 
the NF-kB pathway and stimulation of c-Myc and Sp1 binding to the 
promoter region of the hTERT promoter (27). Telomerase activity 
was assessed by the telomeric amplification protocol assay (TRAP) 
using the TRAPeze telomerase detection kit (Intergen, NY), in IL-2-
dependent or independent, immortalized or transformed, HTLV-I cell 
lines established in vitro. Our results indicated high telomerase 
enzymatic activity in all HTLV-I expressing cells independent of 
their IL-2 requirement status (Fig.1A).  
 
Figure 1:  Increased Telomerase activity in HTLV-I infected cells 
in in vitro and in vivo ATL samples.  (A) TRAP assay in human 
leukemic T-cells lines not infected with HTLV-I (Jurkat and CEM), 
HTLV-I transformed cell lines (MT-2, HUT-102, C91-PL, C10MJ, 
MT-4, and C8166), and IL-2-dependent HTLV-I cell lines (1185, SP, 
and LAF). (B) TRAP assay for detection of telomerase activity in 
AS:  asymptomatic and ATL: adult T-cell leukemia patients.  PBMC: 
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Resting Peripheral Blood Mononuclear Cells served as a control.  
CHAPS buffer and TSR8, served as negative and positive controls 
for telomerase activity, respectively.  The 36 bp internal 
amplification control band (IC) is indicated by an arrow. (C) 
Detection of PinX-1 expression by RT-PCR in ATL and 
asymptomatic patient’s samples. Amplification of GAPDH in non-
saturating conditions was used to normalize RNA samples. Primers 
are described in Table1. 
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We then investigated telomerase activity in in vivo ATL patient’s 
samples. Freshly isolated, uncultured, samples from HTLV-I-
infected asymptomatic (AS) carriers and adult T-cell leukemia (ATL) 
patients were tested for telomerase activity. Resting peripheral blood 
mononuclear cells (PBMC) isolated from a healthy donor not 
infected with HTLV-I were used as a negative control. Telomerase 
activity was much higher in all ATL patients when compared to 
HTLV-I infected asymptomatic carriers and, as expected, control 
resting PBMCs showed no activity (Figure 1B). These findings are in 
agreement with our previous results showing an increased expression 
of the hTERT catalytic subunit mRNA in ATL patients as compared 
to asymptomatic carriers as well as a recent study showing high 
levels of telomerase in ATL patients (32). Recent studies showed that 
the tumor suppressor, PinX1, acts as a potent inhibitor of telomerase 
activity in vitro and in vivo (33).  Expression of many tumor 
suppressors is prevented in ATL cells through either gene deletion or 
promoter hypermethylation (34-36),  raising the possibility that high 
telomerase activity detected in ATL as compared to asymptomatic 
carriers (Fig.1B) resulted from the inactivation of PinX1 expression. 
Analysis of PinX1 mRNA expression in ATL and asymptomatic 
samples showed that this was not the case as expression of PinX1 
mRNA was readily detected in all ATL samples tested (Fig.1C). 
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Although we can not rule out a posttranscriptional inactivation 
mechanism, in absence of a PinX1 specific antibody, expression of 
this protein can not be investigated in ATL samples at the moment 
and warrants further studies. 
 To further investigate whether the high telomerase activity 
present in HTLV-I infected cells may be associated with longer 
telomeres, the average telomere size of HTLV-I cell lines was 
determined by Southern blot analysis (Fig.2A).  
 
Figure 2:  HTLV-I infected cells have short telomeres. (A). 
Southern blot analysis of the telomere lengths in HTLV-I 
transformed (MT2, MT4, C8166, C91PL and C10MJ) and IL-2-
dependent HTLV-I-infected cell lines (LAF and 1185). (B) TRF 
(telomere restriction fragments) average telomere lengths are 
reported. 
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While normal human T-cells have an average telomere size of 15 
Kbp, our results indicated that all HTLV-I established cell lines have 
shorter telomeres, 3.5 to 7 Kbp (Fig.2B). As observed in many solid 
(37) and hematologic cancers (38,39), ATL cells retained shorter 
telomere lengths comparable to the average telomere sizes of other 
human leukemic cell lines not infected with HTLV-I, such as Jurkat 
and CEM (data not shown). Due to the limited amount of samples 
available, the average telomere size of ATL cells cannot be measured 
by Southern blot and was determined by quantitative fluorescence in 
situ hybridization (Q-FISH) using the Telomere PNA /FITC kit. To 
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avoid potential variations in telomere size between different patient’s 
samples, we cell sorted HTLV-I-infected from non-infected cells 
from five uncultured ATL patient samples and compared their 
relative telomere size. As HTLV-I infected ATL cells overexpress 
the CD25 activation marker on their surface, we used anti-CD25-
coupled magnetic beads to sort HTLV-I infected from their non-
infected counterparts. Although regulatory T-cells share the same 
phenotype as ATL cells, CD4+/CD25+, their relative abundance, 
about 5% compared to 50% or more in ATL cells in the peripheral 
blood of acute leukemia ATL patients, is negligible and does not 
affect our assay. Successful sorting was confirmed by staining each 
sorted cell population with an anti-CD25 fluorescein-isothiocyanate 
(FITC)-conjugated antibody, and fluorescence-activated cell sorter 
scanner (FACS) analysis showed at least 95% purity (Fig.3A).  
 
Figure 3:  HTLV-I cell lines and ATL cells have short telomeres. 
(A) CD25 positive and CD25 negative sorted cells analyzed by 
FACS after staining with an anti CD25-FITC conjugated antibody. 
PBMCs were incubated with or without a FITC-conjugated PNA 
telomere probe and analyzed by FACS. (B)  Three ATL patient 
samples were sorted into CD25 positive and CD25 negative cell 
populations and each were subsequently analyzed for integrated 
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HTLV provirus by PCR.  PBMC and MT-2 were used as negative 
and positive controls, respectively.  PCR amplification of GAPDH 
served as a control.  (C) Five ATL patient samples were used for 
CD25 cell sorting and both CD25 positive and CD25 negative cell 
population were analyzed by Q-FISH and telomere sizes calculated 
from two independent measurements. Telomere sizes in PBMC and 
MT-2 were measured by Q-FISH for comparison. 
 
 
To further ensure that CD25+ sorted cells correspond to HTLV-I 
infected cells and not uninfected CD25+ regulatory T-cells (Tregs), 
CD25+ and CD25- cells isolated from PBMCs of a healthy 
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individual and those of an ATL patient were tested by TRAP assay. 
Telomerase activity was only detected in the CD25+ population 
isolated from the ATL patient and no telomerase activity was 
detectable in either population isolated from the non-HTLV-I 
infected donor (data not shown), suggesting that Tregs have barely 
detectable telomerase activity and that the CD25+ cell fraction 
isolated from the ATL patients indeed corresponds to HTLV-I 
infected cells. In fact, integrated HTLV-I provirus was detected by 
PCR in the CD25+, but not CD25- cells isolated from ATL patients 
(Fig.3B). Due to the limited amount of ATL samples available, 
telomere sizes were measured in five patients. Strikingly, our results 
demonstrated that despite the high telomerase activity in HTLV-I-
infected cells from ATL patients, these cells maintained significantly 
shorter telomeres compared to their non-infected PBMC counterparts 
isolated from the same patient (Fig. 3C). For three of the five ATL 
patients, the difference in telomere size, between HTLV-I-infected 
and non-infected cells, averaged a remarkable 10 Kbp shorter in ATL 
cells and reached a significant 3 Kbp for the other two patients tested 
(Fig. 3C). We next investigated whether the maintenance of short 
telomeres in HTLV-I infected cells was dependent on telomerase 
activity. The use of the reverse transcriptase inhibitor, 
 39 
 
azidothymidine (AZT), efficiently reduced telomerase activity in 
various HTLV-I-infected cell lines (Fig.4A).  
 
Figure 4:  Telomerase dependent telomere length maintenance in 
HTLV-I infected cells. 
(A)  TRAP assay in HTLV-I transformed (MT-2) and IL-2-
dependent HTLV-I-infected cell lines (LAF and 1185), as described 
in Figure 1. (B)  Cells were grown continuously with AZT or DMSO 
control for three weeks. Southern blot analysis of telomere lengths in 
HTLV-I cell lines untreated or treated with AZT as described in 
Figure 2. (C) RT-PCR detection of TRF1, TRF2, and TIN2 mRNA 
expression in HTLV-I cell lines untreated or treated with AZT. RNA 
samples were normalized to GAPDH amplification in non-saturating 
conditions. Primers are described in Table1. 
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After 3 weeks of culture in the presence of AZT, HTLV-I infected 
cells had significant reductions in telomere size, suggesting that the 
maintenance of short telomeres requires telomerase, which could be 
used as a potential therapeutic target (Fig.4B). Telomere shortening 
was independent from variations in expression levels of shelterin 
proteins TRF1, TRF2 and TIN2 (Fig.4C). 
 The fact that in ATL patients telomere lengths were 
significantly shorter in virus-infected cells, suggests that despite an 
increased expression of telomerase and telomerase activity, the latter 
may not gain access to the telomeric ends in ATL cells. To 
investigate this hypothesis further, we analyzed mRNA and protein 
expression of telomere-binding proteins, TRF1, TRF2 and POT1, 
known to regulate access of telomerase to the telomere and promote 
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telomere length shortening. Results indicated similar levels of 
expression for TRF1, TRF2 and POT1 in the HTLV-I negative 
human leukemic cell lines Jurkat or HL60, as well as in HTLV-I 
transformed or immortalized cell lines (Figure 5A). We found no 
correlation between HTLV-I transformation status (IL-2 
independent), and the in vitro expression of TRF1, TRF2 and POT1 
genes (Fig.5A and 5B). However, comparison of mRNA extracted 
from HTLV-I transformed MT-4 to PBMCs, indicated the 
overexpression of TRF1, TRF2 and POT1 in human leukemic cells 
and HTLV-I expressing cells (Figure 5A).  
 
Figure 5:  In vitro expression of telomere binding proteins TRF1, 
TRF2, TIN2 and POT-1. (A) Detection of TRF1, TRF2, TIN2 and 
POT-1 mRNA expression by RT-PCR in HTLV-I cell lines and 
leukemic cell lines Jurkat and HL-60.  RNA samples were 
normalized to GAPDH amplification in non-saturating conditions. 
Primers are described in Table1. Comparison of TRF1, TRF2, TIN2 
and POT-1 mRNA expression in MT-4 and PBMC was evaluated by 
RT-PCR. (B) Spot densitometry quantification of mRNA expression 
PBMC (gray bar), HTLV-I negative and positive leukemic cell lines 
in the order shown in A (black bars). Statistical analysis by the 
student t-tests against PBMC control was performed and values are 
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presented. Increased TRF1, TRF2, POT-1 and TIN2 were found to 
be highly significant. (C) TRF1, TRF2, TIN2 and POT-1 protein 
expression was detected by western blot analysis. Equal amounts of 
protein loaded were confirmed by α-actin detection.  
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These results were further confirmed at the protein level by western 
blot analysis of TRF1, TRF2 and POT1 in three HTLV-I cell lines 
(MT-2, MT-4 and C8166) compared to the PBMCs of a HTLV-I 
negative donor (Figure 5C). Previous studies have demonstrated that 
TRF1 and TRF2 interact with double-stranded telomere repeats, and 
that the amount of DNA-bound TRF proteins influences telomere 
length (40). In addition, TRF1 and TRF2 have been shown to interact 
with TIN2, which in turn regulates their activity to modulate 
telomere length. To gain insights into the possible functions mediated 
by the up-regulated expression of TRF genes in HTLV-I infected 
cells, we also investigated the expression of TIN2. As shown in 
figure 5A and 5B, with the exception of MT-2, HTLV-I infected 
cells expressed comparable levels of TIN2 compared to Jurkat or 
normal PBMC. In agreement with previous studies, levels of TIN2 
were low in HL60.  
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 Finally, we analyzed samples isolated from HTLV-I-infected 
asymptomatic and ATL patients. We also included PHA-stimulated 
and resting PBMCs, from an HTLV-I negative donor as an additional 
comparison. No difference was found in the levels of expression of 
TRF1, TRF2 or TIN2 between CD25+ and CD25- purified T-cells 
from resting PBMC of non infected patient (data not shown). 
However we found a significantly higher expression of TRF1 and, to 
a lesser extent, TRF2 in ATL patients as compared to HTLV-I-
infected asymptomatic carriers or PBMC (Figure 6A and B).  
 
Figure 6: Expression of telomere binding proteins TRF1, TRF2, 
TIN2 and POT-1 in uncultured AS and ATL samples.   
(A) Detection of TRF1, TRF2, TIN2 and POT-1 mRNA expression 
by RT-PCR in AS and ATL samples.  RNA samples were 
normalized to GAPDH amplification in non-saturating 
conditions. Primers are described in Table1. (B) Spot 
densitometry quantification of mRNA expression PBMC (gray 
bar), asymptomatic carriers (white bars) and acute ATL (black 
bars). Statistical analysis by the student t-tests between ATL and 
asymptomatic was performed and values are presented. Increased 
TRF1, TRF2 and TIN2 were found to be highly significant.  (C) 
TRF1, TRF2 and TIN2 protein expression was detected by 
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western blot analysis. Equal amounts of protein loaded were 
confirmed by α-actin detection.  
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In contrast, transcriptional levels of POT1 expression did not 
correlate with HTLV-I infection or the disease status (Fig.6A and B). 
The upregulation of TRF1 and TRF2 was confirmed in immunoblots, 
in which an increase in expression of TRF1 and TRF2 was seen in 
comparison to PBMCs (Figure 6C). In clear contrast to the in vitro 
established HTLV-I cell lines, analysis of patient’s samples revealed 
a specific increase in TIN2 expression in ATL, when compared to 
asymptomatic carriers or an HTLV-I negative donor, both at the 
transcriptional and post transcriptional levels (Figure 6A and 6C). 
 
DISCUSSION:  
 
Recent studies have found that short telomeres and high telomerase 
activity are associated with tumorigenesis and poor prognosis in 
cancer patients. In myelodysplastic syndromes, short telomeres 
correlated with an increased risk for transformation to acute leukemia 
and in chronic myeloid leukemia with a worse prognosis (41).   In 
 47 
 
myeloma, cases with high telomerase activity and short telomeres 
had an increased mortality rate (42), and in chronic lymphocytic 
leukemia (CLL) shorter survival was associated with short telomeres 
and high telomerase activity (43). 
Additional reports have shown telomere shortening to be 
associated with the up-regulation of telomere-binding proteins, 
TRF1, TRF2, and TIN2. Gastric carcinomas with short telomere 
lengths expressed significantly stronger telomerase activities along 
with higher TRF1 expression (44).  TRF2 and TIN2 also tended to be 
expressed at higher levels than those with longer telomere lengths.  
In addition, human multistep hepatocarcinogenesis has been shown 
to express higher levels of TRF1, TRF2, and TIN2 (45). 
 Our study is the first to examine the expression of telomerase 
and telomere binding factors in HTLV-I infected cells in vitro and in 
in vivo patient’s samples. We found that in vivo patient’s samples 
from ATL, but not asymptomatic carriers, have high telomerase 
activity in absence of an alteration in PinX1 mRNA expression. The 
telomeres of many human tumor cell lines, in which a high 
telomerase activity is present, do not grow but remain stable at a 
setting characteristic for each individual cell line. Results from our 
quantitative FISH analysis indicated a telomeric length of 10-20 kb 
in normal human T-cells not infected with HTLV-I. However, in all 
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ATL patients analyzed, telomere lengths were significantly shorter 
suggesting that despite an increased expression of telomerase, the 
latter may not gain access to the telomeric ends in ATL cells. The 
telomere size was shown to be dependent upon telomerase activity, 
as treatment of HTLV-I transformed cell lines with a 
pharmacological inhibitor, AZT, caused drastic reduction in 
telomerase activity, followed by a significant decrease in telomere 
lengths.  To account for the shorter telomere lengths seen in ATL 
patients with an increase in telomerase activity, we investigated 
whether telomerase is being limited in its access to telomeric DNA.  
We investigate the expression of telomere-binding proteins TRF1, 
TRF2 and POT1, known to prevent recruitment of telomerase to the 
telomeric ends. While POT1 expression was not specifically affected, 
both TRF1 and TRF2 were over-expressed in ATL samples when 
compared to asymptomatic carriers. It has been reported that over-
expression of TRF1 and TRF2 leads to a progressive shortening of 
telomere length in telomerase-positive cells, possibly facilitating 
genetic instability and tumor progression. However, after an initial 
period of telomere shortening, the telomeres stabilized at a reduced 
length even though TRF1 levels remained high. Thus, increased 
expression of TRF1 and TRF2 may explain the shorter telomeres 
found in ATL cells.  
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Our results are also consistent with a recent report showing that 
tumor cells with short telomere lengths exhibited higher TRF1 
expression and tended to express TRF2. Current research 
demonstrates TRF2’s likely role in regulating the replicative state of 
the cell.  Studies have shown that TRF2 inhibition results in the 
induction of apoptosis in a p53- and ATM-dependent manner (46).  
Furthermore, overexpression of TRF2 likely protects short telomeres 
by reducing the senescence set point in p53-deficient cells, thereby 
extending the proliferative capacity of pre-cancerous cells by 
preventing replicative senescence(47).  We have found TIN2 
expression to be increased in all ATL patients when compared to 
asymptomatic carriers, consistent with similar observations 
demonstrating an increase in TIN2 expression during carcinogenesis 
(48).  TIN2 has been shown to bind TRF1 and TRF2, thereby 
stabilizing TRF2 onto telomeric DNA. The up-regulation of TIN2 
expression, along with TRF1, in patients infected with HTLV-I, may 
therefore, aid in stabilizing TRF2 onto telomeres, consequently 
preventing apoptosis and the activation of the DNA damage response 
pathway in tumor cells with short telomeres (49).  We postulate that 
by protecting such cells, TRF2 and related telomere accessory 
proteins may extend the proliferative capacity and decrease the 
senescence set point in ATL cells. 
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 Our findings suggest that increased expression of TRF1, 
TRF2, and TIN2 may be associated with the establishment and the 
maintenance of short telomeres in ATL patients, which may increase 
chromosomal instability and the risk of progressing to the acute stage 
of ATL. The maintenance of high TRF1 and TIN2 expression may 
prevent apoptotic signals resulting from short telomeres. As telomere 
length is significantly higher in non-tumoral cells from ATL patients, 
interfering with TRF1 or TIN2 expression could lead to specific 
death or senescence of ATL cells, suggesting that these genes 
constitute potential targets for future ATL therapy.  
 
MATERIALS AND METHODS: 
 
Cell Culture: Human leukemia cell lines Jurkat and HL60 and 
HTLV-I-transformed cell lines MT-2, HUT102, C91PL, C10MJ, 
MT-4 and C8166 were cultivated in RPMI 1640 (GIBCO) with 10% 
fetal bovine serum (FBS, GIBCO), supplemented with 2mM 
glutamine, 1% penicillin-streptomycin and 0.4% gentamicin. HTLV-
I-immortalized cell lines 1185, SP, and LAF were cultivated in the 
presence of IL-2 (50U/ml, Roche Molecular). Cells from 
exponentially growing lines were used in the different assays 
described in the study. 
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Patient Samples:  
All patients’ samples were obtained after informed consent was 
received. Clinical data is provided in Table 1. HTLV-I infection was 
confirmed by ELISA and detection of proviral DNA. Acute ATLL 
was defined according to the Lymphoma Study Group of the Japan 
Clinical Oncology Group. Lymphocytes from the peripheral blood of 
healthy volunteers, asymptomatic carriers, or ATL patients were 
purified by Ficoll-Hypaque gradient. Cells were lysed in TriZol 
reagent (Invitrogen) for RNA and DNA extractions. HTLV-I infected 
(CD25+) and uninfected (CD25-) cells, of the same donor, were used 
for telomere length analysis. Sorting was performed using anti-CD25 
magnetic beads (Dynall) according to manufacturer’s instructions. 
Purity was confirmed by staining with anti-CD25 and FACS 
analysis.  
RNA Extraction and RT-PCR: 
Total RNAs were extracted from exponentienally growing cells. 
Potential DNA contaminants were removed by treatment of RNA 
samples with 10U of Deoxyribonuclease I (Invitrogen) in100 μl of 
DEPC treated water containing 4 μl of ribonucleoside vanadyl 
complexes (Sigma) and 160U of RNaseOUT (Invitrogen). Absence 
of DNA contamination in RNA preparations was confirmed by RT-
PCR reactions without a reverse-transcription step (data not shown). 
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RT-PCR was carried out using the OneStep RT-PCR kit (Qiagen) 
according to manufacturer’s instructions.  Appropriate primers, 
indicated in Table 2, were added at a final concentration of 1 μM.  A 
reverse transcription step temperature was set at 50˚C for all samples 
and GAPDH amplification in non-saturating conditions was used as a 
control to monitor RNA quantity and quality. cDNA products were 
visualized by electrophoresis using 1.8% agarose gels stained with 
Ethidium Bromide. 
Telomeric repeat amplification protocol (TRAP) assays  
TRAP assays were performed using the TRAPeze telomerase 
detection kit according to manufacturer's instructions (Intergen, NY). 
Patient samples were lysed in CHAPS buffer and 400 ng (5µl) was 
used per reaction. Extension was performed for 30 minutes at 30°C 
followed by polymerase chain reaction (PCR) as previously 
described. Telomeric products were separated on 8% Tris boric acid 
EDTA (TBE) gel and stained with SYBR Green.  
Telomere length assay by quantitative fluorescence in situ 
hybridization (Q-FISH) and Southern blot. 
The telomere length of CD25 positive and negative cells from ATL 
patients were quantitatively determined by flow cytometry using 
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Telomere PNA /FITC kit  (Dako Cytomation, Carpinteria, CA) 
according to manufacturer’s instructions. Briefly, the sample DNA 
was denatured by incubating cell suspensions at 82˚C for 10 minutes 
and hybridized at room temperature overnight in the dark with or 
without FITC-conjugated PNA telomere probe in the hybridization 
solution. The cells were washed twice with the provided wash 
solution and analyzed by flow cytometry (FACSCalibur, Becton 
Dikinson, San Jose, CA). Southern blots were performed as 
previously reported (50). 
 
Western Blots: 
 Antibodies were as follow: α-actin (C-11, Santa Cruz 
Biotechnology, Santa Cruz, CA), at a dilution of 1:1200.  α-TRF1 
(C-19, Santa Cruz Biotechnology), α-TRF2 (IMG-124, Imgenex, San 
Diege, CA), and α-TIN2 (AM77, Oncogene, San Diego, CA) 
antibodies were used at dilutions of 1:1500, 1:1500, and 1:4000, 
respectively.  α-POT-1 (#978, a gift from T. de Lange) was used for 
cell line immunoblots, using the Guanidine-HCl western protocol.  α-
POT-1 (a gift from C. Harris), used at 1:2000, was used for patient 
immunoblots.  After blocking in 5% nonfat dry milk, all blots were 
incubated overnight at 4oC with primary antibody.  Appropriate 
secondary antibodies were applied for 2 hours at room temperature.  
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Proteins were detected using chemiluminescent substrate solution 
(Pierce, Rockford, IL). 
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Central Role of PI3K in Transcriptional Activation of 
hTERT in HTLV-I Infected Cells. 
 
 
ABSTRACT:   
  
 The persistence of human T-cell leukemia/lymphoma virus-I 
(HTLV-I) infected cells is dependent upon clonal expansion and up-
regulation of telomerase (hTERT).  We previously found that in IL-
2-independent transformed HTLV-I cells, Tax strongly activates the 
hTERT promoter through NF-κB-mediated Sp1 and c-Myc 
activation.  However, in IL-2-dependent cells and ATLL patient’s 
samples, Tax expression is very low, yet these cells retain strong 
telomerase activity suggesting the possible existence of 
compensatory mechanisms.  In this study, we demonstrate that 
telomerase activity is significantly decreased upon IL-2 withdrawal 
from immortalized HTLV-I cell lines.  Inhibition of PI3K or AKT 
signaling pathways drastically reduced telomerase activity in HTLV-
I cells.  We found that IL-2/IL-2R signaling was associated with a 
PI3K-dependent/AKT-independent transcriptional up-regulation of 
the endogenous hTERT promoter.  We also found that the Wilm’s 
Tumor (WT1) protein strongly suppressed hTERT promoter 
expression but not an hTERT promoter mutated for the WT1 binding 
site.  These data demonstrate that activation of the PI3K pathway 
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promotes cytoplasmic retention of WT1, thereby inhibiting WT1 
binding to the hTERT promoter.  The importance of this regulatory 
pathway for telomerase expression is underscored by the findings 
that the PI3K pathway is commonly found activated in cancer cells. 
 
 INTRODUCTION: 
 
 IL-2 (interleukin-2) is required for the differentiation and 
long-term proliferation of T-cells.  IL-2 induces activation of janus 
kinases and signal transducers and activators of transcription 
(JAK/STATs), leading to the induction of Shc/Ras/Raf/mitogen-
activated protein kinase (MAPK) and PI3K/AKT pathways (1).  
These pathways promote cellular proliferation, survival, and 
differentiation (2).  Consequently, they are frequently deregulated in 
hematological malignancies, including B-cell acute and chronic 
lymphoblastic leukemias, T-cell childhood and adult acute 
lymphoblastic leukemias, and various myeloid/lymphoid leukemias.   
 HTLV-I is the causative agent of adult T-cell 
leukemia/lymphoma (ATLL) (3).  During initial infection, HTLV-I 
infected cells are dependent upon IL-2, possibly contributing to the 
early clonal expansion of infected T-cells through an IL-2/IL-2R 
autocrine/paracrine loop. Disease progression, however, occurs in the 
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absence of IL-2 secretion or expression, and when HTLV-I infected 
cells become transformed the cells no longer require IL-2.  While the 
steps leading to IL-2 independence remain to be elucidated, HTLV-I 
transformed cells constitutively express the IL-2R and acquire 
constitutive activation of PI3K and JAK/STAT pathways required for 
the growth of HTLV-I infected cells (4-7). 
 In order to sustain long term proliferation, leukemic cells 
must acquire several oncogenic events – two of which bypass 
apoptosis and replicative senescence.  In in vivo HTLV-I infected 
ATLL cells apoptosis is in part inhibited by increased expression of 
the anti-apoptotic protein, Bcl-xL (8).  The avoidance of replicative 
senescence in ATLL cells is associated with an increase in 
telomerase activity (9), a cellular reverse transcriptase that prolongs 
the lifespan of cells by extending the ends of chromosomes, or 
telomeres.  During successive replication cycles telomerase (hTERT) 
lies down repetitive TTAGGG repeats provided by the template 
RNA (hTR).  While hTR is constitutively expressed in all cells, the 
catalytic subunit of telomerase, hTERT, is transiently expressed, and 
its expression is the rate-limiting step for telomerase activity (10,11).  
 We have shown that hTERT mRNA is overexpressed in 
HTLV-I infected cells and in ATLL patients (12).  In these cells, Tax 
stimulation of NF-κB induced activation of c-Myc and Sp1, thereby 
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upregulating hTERT promoter expression.  We also demonstrated 
that IL-2 dependent and independent HTLV-I cell lines and ATLL 
cells possess strong levels of telomerase activity, independent of their 
transformation status (13).  More importantly, treatment with 
interferon and azidothymidine (AZT), which inhibits telomerase 
activity, results in cellular senescence of HTLV-I infected cells, and 
disease remission in ATLL patients carrying a functional p53 (9).  In 
the present study, we demonstrate that upon IL-2 withdrawal 
telomerase activity is rapidly and substantially reduced in IL-2-
dependent HTLV-I infected cells.  Using inhibitors of downstream 
IL-2R targets, we identified a novel PI3K-dependent/AKT-
independent pathway that potently regulates transcription from the 
hTERT promoter.  
  
RESULTS: 
 
 In agreement with previous studies (14), immunoblot analysis 
revealed high levels of Tax in HTLV-I transformed cells lines (MT-2 
and MT-4) compared to HTLV-I immortalized cell lines (LAF, 1185, 
SP) (Figure 1A).   
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Figure 1.  Removal of IL-2 from HTLV-I immortalized cells 
decreases telomerase activity. (A) Total cell extracts from IL-2 
independent (MT2 and MT4) and IL-2 dependent (LAF, 1185, and 
SP) cell lines were immunoblotted with anti-Tax.  Actin served as a 
loading control. (B) LAF, 1185, and SP cells were cultured in the 
presence (+) or absence (-) of IL-2 for 24 hours followed by TRAP 
analysis for telomerase activity.  TPGs are calculated as the 
percentage of activity compared to cells grown with IL-2 (100%), as 
previously reported9.  (C) LAF cells were analyzed at either 4 hours 
or 24 hours following growth in either IL-2-containing or IL-2-
deprived media.  For each time point, cells were collected and 
analyzed by FACS for cell cycle and TRAP for telomerase activity.  
TPGs are calculated as the percentage of activity compared to cells 
grown with IL-2 (100%).   
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However, HTLV-I immortalized cell lines have levels of telomerase 
activity similar to those of transformed cell lines (13), suggesting that 
in HTLV-I immortalized cell lines, activation of telomerase occurs in 
part through a Tax-independent pathway.  Since HTLV-I 
immortalized cells are strictly IL-2-dependent for long term but not 
short term growth, we hypothesize that IL-2/IL-2R may transduce a 
signal that compensates for the low levels of Tax expression to 
stimulate telomerase activity in pre-leukemic stages.  Consistent with 
this hypothesis, when IL-2 was removed from HTLV cell lines (LAF, 
1185, SP), telomerase activity was significantly decreased (Figure 
1B).  IL-2 withdrawal was less sensitive to 1185 cells compared to 
other HTLV-I immortalized cell lines, probably due to higher levels 
of Tax expression.   
 To determine if IL-2 removal affected cell cycle distribution, 
LAF and 1185 cells were grown in the presence or absence of IL-2 
for 4 and 24 hours.  FACS analysis revealed marginal differences in 
cell cycle distribution between cells cultivated with or without IL-2 
(Figure 1C and data not shown).  Our results demonstrate that IL-2 
withdrawal had no significant effect on cell cycle distribution.  More 
importantly, when cells were grown in the same conditions, 
telomerase activity was decreased but there was no significant effect 
on cell cycle (Figure 1C).  Thus, in agreement with published studies 
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(15,16),  hTERT enzymatic activity is constitutive and not 
significantly affected throughout the cell cycle, independent of IL-2.  
In contrast, accessibility of the telomeric ends by hTERT is restricted 
to the S phase (17).  In addition, the TRAP assay used in this study is 
an in vitro measurement of hTERT activity on a template provided 
by the manufacturer.  Therefore, the TRAP assays are independent of 
cell cycle distribution, as shown by our data. 
 PI3K is a downstream target of IL-2R signaling and is 
constitutively activated in HTLV-I infected cells, where it may be 
required for T-cell transformation (18).  To determine if PI3K has a 
role in telomerase activity, two HTLV-I, IL-2-dependent cell lines 
and two HTLV-I, IL-2-independent cell lines, with constitutive PI3K 
activation, were assayed for telomerase activity following LY294002 
(LY29) treatment, a pharmacological inhibitor of PI3K (19).  Our 
results show a significant decrease in telomerase activity in all cell 
lines tested, confirming that PI3K activation is essential for 
sustaining strong telomerase activity in HTLV-I infected cell lines 
(Figure 2A).   
 
Figure 2.  The PI3K and AKT pathways are associated with 
increased telomerase activity in HTLV-I immortalized and 
transformed cells.  (A and B) IL-2 independent (MT4 and C8166) 
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and dependent (LAF and 1185) cells were treated with LY29 
(LY294002- 10 μM) or control, LY30 (LY303511- 10 μM), for 48 
hours, followed by TRAP analysis for telomerase activity.  In (B), 
cells were treated with AKT Inhibitor II (20 μM) or DMSO control 
(solvent control).  TPGs are calculated as the percent activity 
compared to cells grown without inhibitor (100%).  To verify 
inhibitor efficacy, total cell extracts were immunoblotted with anti-
phosphorylated-AKT (P-AKT).  Anti-AKT served as a loading 
control.  The percentage of decreased expression of P-AKT was 
calculated by spot densitometry as indicated, with cells grown in 
either LY30 or DMSO considered to be 100%.  (C)  HTLV-I cell 
lines, MT4 and LAF, were treated for 48 hours with either LY29 
(10μM), AG490 (50 μM), or control DMSO.  Cells were 
subsequently stained for Annexin V and propidium iodine (PI), and 
analyzed for apoptosis by FACS analysis.  The percentage of dead 
cells for each treatment is indicated.  (D) 1185 and LAF cells were 
cultivated without IL-2 and in the presence of LY29 (10 μM) for 48 
hrs.  Following the 48 hr incubation period, the cultures were split 
and IL-2 was added in the absence or presence of LY29 (10 μM) for 
an additional 24 hrs.  TRAP analysis was performed and TPGs are 
calculated as the percentage of activity compared to cells grown 
without treatment (100%).  For a positive control, cells were grown 
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for 48 hrs without IL-2, then treated an additional 24 hrs without IL-
2, and with or without LY29 (10 µM).  Cells grown continuously in 
IL-2 served as a negative control.     
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To verify the efficacy of LY29 treatment, cell extracts were assayed 
for AKT phosphorylation, a downstream target of PI3K.  Western 
blot analysis showed decreased AKT phosphorylation at Ser473, 
while levels of AKT remained unchanged.   
 The Tax protein of HTLV-I has been shown to stimulate 
AKT activity (20), a target of PI3K signaling.  Inhibition of AKT, 
following treatment with the specific inhibitor, AKT Inhibitor II 
(AKT II), resulted in decreased telomerase activity in both 
immortalized and transformed HTLV-I cell lines (Figure 2B).  This 
is in agreement with published reports, in which AKT increased 
telomerase activity by phosphorylating hTERT, thereby increasing 
hTERT activity at the posttranscriptional level (21).   
 Previous studies have reported growth inhibition and 
induction of apoptosis upon treatment with LY29 and AG490, a Jak 
inhibitor (22,23). To demonstrate that loss of PI3K signaling, and not 
an increase in cellular death, caused the decrease in telomerase 
activity, we treated MT4 and LAF cells with LY29 or AG490 for 48 
hours and analyzed cells for apoptosis by annexin V/propidium 
iodine (PI) staining. AG490 was used as control, because our data 
showed no effect of AG490 on telomerase activity (data not shown).  
FACS analysis demonstrated marginal increases of 0.1% and 0.8% in 
cell death for MT4 and LAF cells, respectively, upon treatment with 
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LY29 (Figure 2C).  Treatment with AG490, caused a slightly greater 
increase in MT4 and LAF cell death, (0.8% and 4.5%, respectively).  
These results are in agreement with a previously published report, in 
which treatment with AG490 did not inhibit proliferation in HTLV-I 
cell lines (24).  Since AG490 had no effect on telomerase activity, 
these data demonstrate that inhibition of telomerase activity by 
LY29, is due to inhibition of the PI3K-pathway and independent 
from cellular death.   
 To confirm the role of the IL-2/IL-2R/PI3K pathway in 
stimulation of telomerase activity, we cultured 1185 and LAF cells in 
media without IL-2 and with LY29 for 48 hours.  These cells were 
then divided into cultures with IL-2 in the presence or absence of 
LY29 for an additional 24 hours.  IL-2 pulse increased hTERT 
activity only when LY29 was absent (Figure 2D).  Unlike 1185 cells, 
LAF cells pulsed with IL-2 did not completely rescue telomerase 
activity in 24 hours.  This could be do to the lower amount of Tax in 
LAF cells, or a longer period of recovery is needed.  These data 
suggest that most of the IL-2R signaling involved in hTERT 
promoter regulation occurs through the IL-2/IL-2R/PI3K pathway.  
As a control, cells were grown in the absence of IL-2 for 48 hours, 
followed by treatment with or without LY29.  As was expected, 
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telomerase activity decreased following IL-2 removal, which was 
further decreased upon LY29 treatment (Figure 2D).  
 
The PI3K pathway transcriptionally regulates hTERT expression 
in HTLV-I infected cells. 
 
 To determine whether PI3K and AKT signaling acted at the 
transcriptional and/or post-transcriptional levels, we treated 1185 
cells with PI3K and AKT inhibitors for 4 hours.  Quantitative real-
time PCR revealed a rapid and considerable loss of hTERT 
expression following treatment with LY29, which was not seen to the 
same extent with treatment with AKT II (Figure 3A).  
 
Figure 3.  Telomerase activity is regulated at the level of 
transcription by a PI3K-dependent pathway in HTLV-I cell 
lines.  (A) 1185 cells were treated with LY29 (10 μM), AKT II (20 
μM), LY29 (10 μM)/AKT II (20 μM) or DMSO (solvent control) for 
4 hours, followed by analysis of hTERT RNA expression by 
quantitative real-time PCR.  GAPDH expression was used as a 
control.  Time 0 hrs indicates cells prior to inhibitor treatment.  (B-D) 
1185 cells were treated with LY29 (10 μM), AKT II (20 μM), 
LY29/AKT II (10 μM/20 μM), or DMSO (solvent control) for 48 
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hours, followed by TRAP analysis for telomerase activity (B), FACS 
analysis for cell cycle (C), or FACS analysis for apoptosis (D).  
TPGs are calculated as the percentage of activity compared to DMSO 
(100%).  (E)  1185 cells were grown with or without IL-2 for 4 hours 
followed by western blot analysis.  Nuclear extracts were probed 
with anti-NF-κB RelA/p65, and cytoplasmic extracts with anti-IκB-α. 
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Treatment with a combination of LY29 and AKT II lead to a 
decrease in hTERT expression comparable to treatment with LY29 
alone, suggesting that PI3K is the primary regulator of hTERT 
expression at the transcriptional level.  Because PI3K, and not AKT 
inhibition, led to significant transcriptional repression of hTERT 
(approximately 80%), our results suggest that PI3K regulates 
telomerase activity through an AKT-independent pathway 
(transcriptional).  To verify this hypothesis, 1185 cells were treated 
with a combination of PI3K and AKT inhibitors. Results indicated 
that treatment with both inhibitors affected telomerase activity to a 
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much larger extent than treatment with either drug alone (Figure 3B), 
thereby demonstrating that PI3K and AKT have an additive, 
independent effect on telomerase activity.  These effects were 
independent of cell cycle distribution (Figure 3C) or cell death 
(Figure 3D), as demonstrated by FACS analysis of PI staining and 
AnnexinV/PI staining, respectively. 
 A downstream target of PI3K/AKT signaling is NF-κB.  NF-
κB increases hTERT activity transcriptionally and post-
transcriptionally:  the former, by nuclear translocation of hTERT 
through p65-mediated interactions (25), and the latter, by increases in 
c-Myc and Sp1 expression (26). Since Tax can directly stimulate NF-
κB through activation of PI3K, AKT, and IKK, we did not expect to 
see a difference in NF-κB-mediated control of hTERT upon IL-2 
withdrawal.  As expected, 1185 showed no significant differences in 
nuclear RelA/p65 or IκB-α expression following removal of IL-2 
from the culture media (Figure 3C).  
 We next assayed the effect of IL-2 on hTERT promoter 
expression in HTLV-I infected cells. We found a strong decrease in 
hTERT expression only 4 hours after IL-2 removal in both 1185 and 
LAF cells, and hTERT expression was completely suppressed after 
24 hours (Figure 4A).   
 
 80 
 
Figure 4.  IL-2R/IL-2 signaling regulates hTERT promoter 
expression.  (A) IL-2 was withdrawn from 1185 and LAF cells for 4 
or 24 (overnight – O/N) hours, followed by hTERT RNA expression 
by RT-PCR. (B)  LAF cells were cultured in the absence of IL-2 for 
4 hours, and subsequently pulsed with IL-2 for 4 and 24 hours prior 
to hTERT RT-PCR analysis.  Cells grown continuously in IL-2 
media served as a control (first lane)  (C)  1185 cells were treated 
with actinomycin D (5 μg/ml) in the presence or absence of IL-2 for 
0, 1, 2, and 4 hours.  RNA was extracted and analyzed for hTERT 
expression by RT-PCR.  For (A-C), GAPDH was used as an 
amplification control. 
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In order to demonstrate that IL-2 removal was responsible for 
transcriptional control of hTERT expression, LAF cells were 
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cultivated in the absence of IL-2 then pulsed with IL-2. Results 
indicated that hTERT expression levels were increased in less than 4 
hours and restored to the original levels after overnight culture with 
IL-2 media (Figure 4B).  This confirms a potent and rapid effect of 
IL-2R signaling on hTERT expression.  Because our data showed a 
sudden loss of hTERT RNA levels in only 4 hours, we next looked at 
the stability of the RNA transcript by measuring the half life of the 
hTERT mRNA in1185 cells cultured in the presence or absence of 
IL-2. Our results indicated no difference in hTERT half-life (around 2 
hours) in 1185 cells cultivated in the presence or absence of IL-2 
(Figure 4C).  These results are consistent with the previously 
reported half-life of hTERT mRNA (about 2 hours) (27) and suggest 
that the effect of IL-2 removal mainly occurs at the transcriptional 
level in absence of hTERT RNA destabilization.  
 
The activation of PI3K signaling pathways in HTLV-I infected 
cells, results in cytoplasmic retention of WT1, a negative 
regulator of hTERT expression.  
 
 Protein phosphatase 2A (PP2A) lies directly downstream of 
PI3K and targets AKT and protein kinases A and C (PKA and PKC).  
PKC acts as a post-transcriptional regulator of telomerase, by 
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phosphorylating hTERT and allowing for assembly of the 
holoenzyme complex (28).  In contrast, PKA increases 
phosphorylation of the Wilm’s tumor suppressor (WT1) protein, a 
potent transcriptional repressor that inhibits hTERT expression by 
direct binding to the hTERT promoter (29).  PKA-mediated 
phosphorylation of WT1, sequesters WT1 in the cytoplasm (30,31).  
Consistent with this model, and the constitutive activation of PI3K 
found in HTLV-I infected cells, we observed a prominent 
cytoplasmic distribution of WT1 in MT4 and 1185 cells (Figure 5A).   
 
Figure 5.  Cellular localization of WT1 dictates repression of 
hTERT expression.  (A) MT4 and 1185 cells were treated with 
LY29 (10 μM) or DMSO (solvent control) for 48 hours followed by 
immunostaining with anti-WT1 (Green).  Nuclear staining was 
visualized by DAPI (Blue).  (B) 1185 cells were cultured overnight 
with or without IL-2 and stained with anti-WT1, as described above.  
(C)  The HTLV-I transformed cells, MT2 and MT4, or the HTLV-I 
immortalized cells, 1185, were electroporated with the hTERT-Luc-
Promoter using the Amaxa transfection kit.  12 hours post-
transfection, MT2 and MT4 cells were treated with either LY29 (10 
μM) or DMSO (solvent control) for 8 hours. 1185 cells were 
electroporated and cultured in media with and without IL-2 for 24 
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hours.  Cell extracts were normalized and assayed for luciferase 
activity.   
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However, inhibition of PI3K, by treatment with LY29 in HTLV-I 
infected cell lines, caused a redistribution of WT1 to the nucleus. 
Importantly, similar results were obtained upon IL-2 removal, which 
was not seen upon AKT inhibition, in 1185 cells (Figure 5B).  These 
results demonstrate that IL-2R signaling, via PI3K, leads to 
cytoplasmic retention of WT1, effectively preventing WT1 from 
reaching and repressing the hTERT promoter.   
 To confirm the role of IL-2/IL-2R signaling through PI3K on 
hTERT expression in HTLV-I infected cells, we electroporated MT2 
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and MT4 cells with the hTERT luciferase vector.  Consistent with the 
results described above, inhibition of PI3K by LY29, reduced 
hTERT luciferase activity by 32% and 34% for MT2 and MT4 cells, 
respectively (Figure 5C).   In the HTLV-I immortalized cell line 
1185, we found a 28% reduction in hTERT luciferase promoter 
transactivation when cells were grown for 24 hours in media without 
IL-2 compared to cells grown with IL-2.  The differences in hTERT 
transactivation in the 1185 luciferase assays (28% reduction) 
compared to the endogenous levels of hTERT expression 
(approximately 80% reduction) seen in Figure 3A, are probably due 
to the presence of multiple copies of the hTERT luciferase plasmid 
upon Amaxa transfection.  In such conditions, the limiting amounts 
of WT1 in HTLV-I infected cells would explain that the suppression 
of the hTERT luciferase promoter upon transfection is not as 
pronounced as compared to the endogenous hTERT promoter.   
 To further characterize the role of IL-2R signaling on WT1 
activity, we performed a biotin-pull-down assay using the hTERT 
promoter as bait.  We found that cells cultured in the absence of IL-2 
had a significant increase (45%) in WT1 binding to the hTERT 
promoter, thereby explaining the repression of hTERT expression 
(Figure 6A).   
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Figure 6.  IL-2-dependent WT1 binding to the hTERT promoter.  
(A) The hTERT-3915 promoter was biotin-labeled and bound to 
streptavidin-agarose beads, followed by incubation with 1185 
cellular extracts from cells cultivated overnight in the presence or 
absence of IL-2.  Bound proteins were visualized using anti-WT1 or 
anti-c-Myc.  The percentage of increased binding of WT1 to the 
hTERT promoter was calculated by spot densitometry as indicated, 
with 1185 cells grown in the presence of IL-2 considered to be 
100%.  (B) 293T cells were transfected with wild-type WT1 (SS – 
normal serines) or mutant WT1 (FF – mutated serines to 
phenylalanines), along with the hTERT-Luc promoter, or wild-type 
WT1 (SS) or mutant WT1 (FF), along with the hTERT-Mut-Luc 
promoter (defective for WT1-binding). Extracts were assayed 48 hrs 
post-transfection for luciferase activity (experiments performed in 
duplicate).  Cell extracts were probed with anti-WT1 and anti-actin 
to verify expression.  Average luciferase values were as follows:   
hTERT-Luc promoter (150,518), +WT1(SS) (79,578), +WT1(FF) 
(241,727) and for the hTERT-Mut Luc promoter (890,681), 
+WT1(SS) (686,143), +WT1(FF) (2,184,084).   
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Increased binding of WT1 was due to an increase in DNA binding 
affinity, rather than overall levels, as shown by equal input of WT1 
and c-Myc.  In fact, it has been shown that PKA-mediated 
phosphorylation of WT1 impairs both its nuclear localization and its 
DNA binding activity (30).  As an internal control for this assay, the 
levels of c-Myc bound to the hTERT promoter did not change in 
response to IL-2 withdrawal.   To confirm that WT1 is a 
transcriptional repressor of the hTERT promoter, we transfected 
wild-type WT1 into 293T cells along with an hTERT luciferase 
construct.  hTERT promoter activity decreased by approximately 
50% (Figure 7B).  In contrast, a mutant WT1 (WT1-KK), which 
cannot be phosphorylated by PKA, was unable to repress the hTERT 
promoter.  To further demonstrate that the WT1 effect was mediated 
by direct binding, we mutated the WT1 binding site 
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(GCGCGGGCG) (29) within the hTERT luciferase vector.  This 
hTERT promoter luciferase construct (hTERT-MUT-Luc) was no 
longer repressed to the same extent as the wild-type hTERT promoter 
upon co-expression of WT1 (Figure 6B). Our data demonstrate that 
through activation of the PI3K pathway, WT1 is sequestered in the 
cytoplasm of HTLV-I infected cells contributing to the overall 
elevated telomerase activity seen during HTLV-I infection. 
 
DISCUSSION: 
 
Tax plays an important role in the early steps of 
transformation by HTLV-I through deregulating host cell signaling 
pathways, including those involved with cell cycle, apoptosis, and 
proliferation. We have previously shown Tax stimulates high 
telomerase activity in HTLV-I infected cells (12). However, IL-2 
dependent cell lines express very little Tax, yet retain the high levels 
of telomerase activity seen in transformed cell lines.  Here, we 
demonstrate that HTLV-I cell lines rely upon IL-2R signaling 
pathways to sustain high telomerase activity, in absence of high Tax 
expression. 
In order to gain a better insight into IL-2- and Tax-mediated 
regulation of telomerase activity, we looked at the level of hTERT 
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expression. In absence of exogenous IL-2, Tax can lead to PI3K and 
AKT stimulation. In accordance, inhibition of downstream IL-2R 
targets, PI3K and AKT, leads to a significant loss of telomerase 
activity in both immortalized and transformed cell lines, from 25 to 
75%.  Importantly, such levels of repression were previously shown 
to be sufficient for telomere attrition and induction of senescence in 
HTLV-I infected cells (9).  AKT inhibition had marginal effects on 
hTERT promoter expression, consistent with its role as a post-
transcriptional regulator of telomerase activity (21).  In contrast, we 
found that PI3K inhibition substantially decreased hTERT 
expression, suggesting that a PI3K-dependent/AKT-independent 
pathway controls hTERT transcription.  PI3K stimulates PKA, which 
phosphorylates WT1, leading to its cytoplasmic retention (30,31). By 
sequestering WT1 in the cytoplasm, HTLV-I infected cells remove a 
negative regulator of hTERT expression. We previously 
demonstrated c-Myc and Sp1 have increased binding to the hTERT 
promoter upon transfection of Tax. We now report a new mechanism 
by which HTLV-I increases hTERT activity, by relieving WT1-
mediated hTERT promoter repression. The biological significance of 
our data is underscored by the fact that similar levels of telomerase 
inhibition, as those reported here, by AZT have been shown to 
induce p53-dependent senescence and death of HTLV-I cells lines 
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and ATL patients (9). Therefore, IL-2 may be required in the early 
stages of transformation to ensure high telomerase activity and 
extend the life span of infected cells, therefore; increasing the risk of 
cumulative genetic defects and transformation. 
WT1 is expressed in Wilms’ tumors, colon cancer, breast 
cancer, and leukemia (32).  In hematopoietic cells, WT1 behaves like 
a tumor suppressor, promoting differentiation by decreasing cellular 
proliferation, contributing to growth arrest, and reducing colony 
formation (33,34).  However, it has been suggested that WT1 acts as 
an oncogene in leukemic cells as it is highly expressed in the 
peripheral blood of many leukemias (32). Our study supports a role 
for WT1 as a tumor suppressor gene in HTLV-I infected cell lines, 
by decreasing the level of telomerase expression. Decreased 
telomerase activity in cancer cells has been linked to cellular 
senescence and death. WT1 expression is elevated in leukemias 
beyond the levels found in normal hematopoietic cells. The use of 
RNA interference and antisense oligonucleotides against endogenous 
WT1 in acute myeloid leukemia (AML) and chronic myelogenous 
leukemia (CML) cell lines, including leukemia patient samples, leads 
to decreased growth and apoptosis (35,36).  HTLV-I infection may 
allow for WT1 expression to enhance the proto-oncogenic effects 
required for tumor proliferation, while at the same time inhibiting 
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WT1’s transcriptional suppressive functions by sequestering the 
protein in the cytoplasm to allow for elevated telomerase activity.  
Our study was performed in HTLV-I infected cell lines, 
which express high levels of Tax.  However, Tax is barely detectable 
in ATLL leukemic cells (37,38), yet these cells maintain high levels 
of telomerase expression and activity (12,13).  We propose that 
ATLL patients may rely upon an IL-2R signaling pathway similar to 
those in HTLV-I immortalized cell lines to maintain high telomerase 
activity, in absence of Tax expression.  This is supported by the fact 
that ATLL cells have constitutive activation of the high affinity IL-
2R (39).   Future studies, in which IL-2R components, especially the 
PI3K pathway, are inhibited through siRNA-mediated inhibition, 
could verify this.  It remains to be clarified whether PI3K is 
responsible for retaining WT1 in the cytoplasm, and whether 
additional IL-2R signaling pathways are activated and/or repressed in 
order to enhance telomerase expression in ATLL patients. 
 In conclusion, our data suggests an important role for the 
PI3K pathway in transcriptional regulation of hTERT and 
underscores the importance of this regulatory pathway for telomerase 
expression in cancer cells, especially given the fact that the PI3K 
pathway is commonly found activated in tumor cells.  
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MATERIALS AND  METHODS: 
 
Cell Culture  
 The HTLV-I transformed cell lines, MT4, MT2, and C8166, 
and the HTLV-I immortalized cell lines, LAF, SP, and 1185, were 
cultivated in RPMI 1640 with 10% fetal bovine serum and, when 
indicated in the text, IL-2 (50 U/ml).  293T cells were grown in 
DMEM.  HTLV-I cell lines were treated with either 20 µM AKT 
Inhibitor II (Calbiochem), 10 µM  LY294002 (Sigma), or 50 µM 
AG490 (Biomol), as indicated in the figure legends. Treatment with 
either Dimethyl sulfoxide (DMSO) or LY303511 (Sigma) served as 
negative controls.  
 
Telomeric Repeat Amplification Protocal Assays (TRAP) 
 TRAP assays were performed using the TRAPeze telomerase 
detection kit according to the manufacturer’s instructions (Intergen, 
NY).  Quantification of the total product generated (TPG) was 
performed using the following equation:  [(x-x0)/c]/[(r-r0)/cR] x 100, 
where (x) is the TRAP product generated in the sample, (x0) is the 
TRAP product generated in the heat-treated sample, (c) is the internal 
control band for the sample, (r) is the TSR8 quantitation control, (r0) 
is the 1x CHAPS lysis buffer control, and (CR) is the TSR8 
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quantitation internal control band.  Telomeric products were 
separated on 8% tris boric acid EDTA gels and stained with SYBR 
green for visualization. Standardization of the assay and appropriate 
controls in our laboratory have been previously reported (9).  
 
RNA extraction, RT-PCR, and Real-Time PCR. 
 Total RNA was extracted using Trizol (Invitrogen).  Prior to 
analysis, DNA contamination was removed from RNA samples as 
previously described (13).  RT-PCR was performed in non-saturating 
conditions using the OneStep RT-PCR kit (Qiagen), according to the 
manufacturer’s instructions.  RT-PCR was performed with the 
following sets of primers:  hTERT, F:  5’-CTG GGT GGC ACG 
GCT TTT GTT C-3’ and R:  5’-CCC CGG GAG CTT CCG ACT-3’ 
and GAPDH, F:  5’-GAA GGT GAA GGT CGG AGT C-3’ and R: 
5’-GAA GAT GGT GAT GGG ATT TC-3’.  RT-PCR was 
performed without the reverse transcriptase step to verify absence of 
DNA.  cDNA for Real-time PCR was generated using the 
Transcriptor first strand cDNA synthesis kit (Roche).  The cDNA 
was diluted (1:2) and Real-time PCR was performed using the RT2 
SYBR Green/ROX qPCR Master Mix (SuperArray), with the 
following hTERT primers, F:  5’-GCG GAA GAC AGT GGT GAA 
CT-3’ and R:  5’-AGC TGG AGT AGT CGC TCT GC-3’  
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Western Blots 
 Cells were lysed in RIPA and subject to western blotting 
using the following sets of antibodies:  monoclonal anti-Tax (NIH 
AIDS Reagent Repository), c-Myc (A-14, Santa Cruz), WT1 (C-19, 
Santa Cruz), α-actin (C-11, Santa Cruz), AKT (9272, Cell Signaling) 
and Phospho-Akt (Ser 473) (9271, Cell Signaling).  For western blots 
following IL-2 withdrawal, the cell pellets were lysed in hypotonic 
buffer (10mM HEPES, pH 7.9, 1mM MgCl2, 0.5mM NaCl, 0.5% 
NP-40), then centrifuged.  The supernatant was collected for 
cytoplasmic proteins and the cell pellet was lysed in hypertonic 
buffer (5mM HEPES, pH 7.9, 5mM MgCl2, 0.1mM EDTA, 0.4M 
NaCl, 1mM DTT).  Following centrifugation, the supernatant was 
collected for nuclear proteins.  Western blots were then performed 
using NF-κB p65 (A, Santa Cruz), c-Myc (A-14, Santa Cruz), and 
IκB-α (H-4, Santa Cruz).  All secondary antibodies were from Santa 
Cruz.  
 
Cell Cycle Analysis 
 Cells were cultured with and without IL-2 or treated with 
LY29 (10 µM) and/or AKT II (20µM) as indicated.  Cells were fixed 
with 80% EtOH for 30 minutes on ice, followed by treatment with 
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RNase for 15 minutes at 37oC.  Cells were then stained with 50 
μg/ml propidium iodine for 15 minutes at room temperature.  Cell 
cycle was analyzed by flow cytometry.   
 
Annexin V/PI Staining 
 HTLV-I infected cells were treated for 48 hours with either 
LY29 (10μM), AG490 (50 μM), AKT II (20µM), or DMSO control.  
Following treatment, cells were collected and stained with annexin V 
(FITC)/propidium iodine using the Vybrant Apoptosis Assay Kit 
no.2 (Molecular Probes), according to the manufacturer’s 
instructions.  Apoptosis was analyzed by flow cytometry. 
 
Immunofluorescence 
 HTLV-I infected cells were treated with or without LY29 
(10μM) for 48 hours and/or cultivated with or without IL-2 
overnight.  Following treatment, cells were fixed with 4% 
paraformaldehyde and permeabilized using 0.5% Triton X-100. Cells 
were then incubated in blocking buffer (10% BSA and 0.1% Tween 
20), followed by incubation with WT1 antibody (C-19, Santa Cruz).  
Secondary body was Alexa Fluor 488 goat α-rabbit IgG (Molecular 
Probes).  Slides were stained with DAPI and images were captured 
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using a Nikon EFD3 microscope (Boyce Scientific) and Nikon 
camera (100X Eplan (160/0.17) objective).   
 
Biotin Pull-Down Assay 
 The hTERT promoter was isolated from the hTERT-Luc-
3915 plasmid (a generous gift from I. Horikawa) and labeled with 
C14-biotin (Invitrogen). Labeled DNA was bound to streptavidin-
agarose beads and incubated with protein extracts from cells cultured 
with or without IL-2 for 24 hours. The pull-down was subsequently 
washed in binding buffer (10 mM Tris [pH 7.05], 50 mM NaCl, 
50 mM NaF, 0.2 mM Na3VO4, 30 mM Na2P2O7, 5 µM ZnCl2, 0.5% 
Triton X-100) and bound proteins were analyzed by western blot. 
 
Luciferase 
 Luciferase assays were performed with the Luciferase 
Reporter Assay Kit (Promega). 293T cells were co-transfected with 
the hTERT-Luc-3915 vector, along with either wild-type WT1 (SS) 
or mutant WT1 (FF) expression vectors (generous gifts from 
T.Hunter from the Salk Institute).  All transfections were performed 
using Polyfect (Qiagen). The binding site for WT1 in the hTERT-
Luc-3915 promoter (GCGCGGGCG) was mutated to 
(GCGAAGGCG) using the QuickChange II XL site-directed 
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mutagenesis kit (Stratagene), according to the manufacturer’s 
instructions.  DNA was sequenced to verify the correct mutations.  
HTLV-I infected cell lines were transfected using Nucleofector Kit V 
(Amaxa Biosystems), according to manufacturer’s instructions.  12 
hours post-transfection, MT4 and MT2 cells were treated with either 
LY29 (10 μM) or DMSO control for 8 hours.  For IL-2 withdrawal, 
1185 cells were cultivated in media with and without IL-2 for 24 
hours.   
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Persistent inhibition of telomerase reprograms 
adult T-cell leukemia to p53-dependent 
senescence. 
 
 
 
ABSTRACT: 
 
The antiviral thymidine analog azidothymidine (AZT) is used to treat 
several virus associated human cancers. However, to date the 
mechanism of AZT action remains unclear and thus, reasons for 
treatment failure are unknown. Adult T-cell leukemia/lymphoma 
(ATL) is an aggressive malignancy of poor prognosis. Here, we 
report that enduring AZT treatment of HTLV-I infected cells, in 
vitro, and in vivo ATL patients, results in inhibition of telomerase 
activity, progressive telomere shortening and increased p14ARF 
expression. In turn, this elicits stabilization and reactivation of the 
tumor suppressor p53-dependent transcription, increased expression 
of the cyclin-dependent kinase inhibitor p21Waf1 and accumulation of 
p27kip1, thereby inducing cellular senescence and tumor cell death. 
While ATL patients carrying a wild type p53 enter remission 
following treatment with AZT, those with a mutated p53 did not 
respond and patient’s disease relapse was associated with the 
selection of a tumor clone carrying mutated inactive p53.  
 104 
 
 
INTRODUCTION: 
 
 Adult T-cell leukemia is etiologically linked to the human T-
cell leukemia virus type I (HTLV-I) (1,2). HTLV-I-mediated T-cell 
transformation presumably arises from a multi-step oncogenic 
process in which the virus induces chronic T-cell proliferation 
resulting in an accumulation of genetic defects and the deregulated 
growth of infected cells [3]. Since its discovery many aspects of 
HTLV-I biology have been uncovered however treatments of the 
diseases remain disappointing with minimal improvement in the 
overall survival of patients. The poor prognosis of ATL patients is 
associated with the resistance of neoplastic cells to the conventional 
combination of high-dose chemotherapy and radiotherapy [4]. 
Recently, a higher response rate following AZT/ IFN alpha treatment 
of ATL patients has been reported in several human trials [5-7]. 
However, the mechanism of action of AZT/ IFN remains unknown 
and therefore predictive markers for prognostic therapy are not 
available. Several human cancers have been treated using anti-
retroviral AZT, including, AIDS-related Kaposi sarcoma [8]; Kaposi 
sarcoma associated primary effusion lymphoma (PEL), EBV-
associated lymphoma [9] and primary central nervous system 
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lymphoma (PCNL) [10]. In vitro treatment of PEL cell lines with 
AZT resulted in TRAIL-dependent apoptosis [11;12] along with NF-
kB inhibition and apoptosis in EBV-associated Burkitt lymphoma 
[13]. In contrast, remission of ATL patients treated with AZT follows 
a slow kinetic over several months, suggesting that a non apoptotic 
pathway may be involved. These observations prompted us to 
investigate the long term potential effects of AZT on telomerase and 
telomere functions. Since DNA polymerase is unable to replicate the 
very end of linear DNA, every replication cycle leads to a 
progressive shortening of the telomeric ends and to the limited 
proliferative capacity of normal cells termed "replicative 
senescence." Activation of human telomerase, an RNA-dependent 
DNA polymerase that elongates telomeres, has been proposed as a 
mechanism for avoiding telomere shortening. Consistent with this 
model, most cancer cells, including HTLV-I infected cells, have 
detectable telomerase activity, as opposed to normal somatic cells 
[14]. In some cases, immortalized cells do not have any detectable 
telomerase activity in spite of long telomere length, suggesting the 
existence of an alternative mechanism referred to as ALT and 
characterized by specific makers [15]. 
 Here we report that enduring treatment of HTLV-I infected 
cells with AZT result in telomere attrition and reactivation of p53 
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transcriptional activities leading to senescence of tumor cells. 
Importantly, in vivo treated ATL patients responded to therapy only 
when p53 was wild type in sequence and inversely disease relapse or 
absence of response to treatment was associated with mutation and 
inactive p53. Our results indicate that p53 is a predictive marker and 
a response to AZT therapy requires a functional p53 gene. 
 
RESULTS: 
 
Inhibition of telomerase induces telomere attrition and cell death 
in HTLV-I transformed cell lines. 
 We and others have reported that HTLV-I infection is 
associated with increased telomerase activity in transformed cells in 
vitro and in vivo [16-19]. As expected, treatment of HTLV-I 
transformed cell lines with telomerase inhibitors, AZT or ddG, 
resulted in a marked reduction of telomerase activity in HTLV-I 
infected cells (Fig.1A).  
 
Figure 1: Telomerase inhibition induces senescence in HTLV-I 
infected cells.  
(A) Telomerase activity (expressed as telomeric product generated, 
TPG), measured by TRAP assay in HTLV-I cell lines in absence of 
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or presence of telomerase inhibitors AZT (50μM) and ddG (10μM) 
for 72 hours. (B) Correlation between telomerase activity (TPG) and 
survival of AZT treated HTLV-I cell lines (in weeks). (C) Inhibition 
of telomerase activity by AZT in the HTLV-I transformed MT-2 cell 
line untreated or treated with AZT for 18 weeks. (D) Southern blot 
analysis of telomere shortening following AZT treatment.  
 
 
As telomerase activity is required for continual proliferation and 
avoidance of replicative senescence of tumor cells, we evaluated the 
long term effects of telomerase inhibition by maintaining HTLV-I 
cell lines in medium supplemented with AZT or ddG. While short 
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term treatment had no effect on proliferation or survival (data not 
shown and [20]), all HTLV-I cell lines ceased to grow, entered 
senescence (Fig.1B) and died after several weeks of culture in the 
presence of AZT or ddG, as observed by cell counts and trypan blue 
exclusion (data not shown). Longer survival, as observed in MT-2 
and HUT-102, appeared to be associated with a lower telomerase 
activity compared to C10MJ and LAF (Fig.1B and data not shown). 
In contrast, the Jurkat T-cell line, treated under the same conditions, 
did not enter growth arrest (data not shown), in spite of significant 
telomere shortening as previously reported [21]. HTLV-I 
transformed cells do not acquire resistance to AZT-mediated 
inhibition of telomerase activity even after a prolonged period of 
treatment because residual activity present in long term treated cells 
(Fig1C, lane 3) can be further inhibited in MT-2 as well as in other 
HTLV-I cell lines by addition of AZT for 48 hours (Fig.1C lane4, 
and data not shown). Analysis of telomere length by Southern blot 
revealed a progressive shortening in all HTLV-I cell lines cultured in 
continuous presence of AZT (Fig.1D). 
 
AZT induces senescence of HTLV-I infected cells  
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 As telomere shortening has been associated with 
chromosomal instability causing either apoptosis or senescence 
[22;23] , we investigated the mechanism of tumor cell death in long 
term AZT-treated cells. Previous studies reported that EBV-positive 
Burkitt lymphoma cells from AIDS patients respond in vitro to AZT 
by undergoing caspase-dependent apoptosis. HTLV-I infected cells 
are protected from apoptosis in part through high levels of Bcl-2 and 
Bcl-xL expression [24]. However the expression of pro-apoptotic and 
anti-apoptotic proteins remained unchanged in long term AZT-
treated MT-2 cells (Fig.2A).  
 
Figure 2: Persistent telomerase inhibition is not associated with 
apoptosis but induces senescence in HTLV-I infected cells. (A) 
Western blots analysis for expression of apoptosis regulators in 
untreated MT-2 or treated with AZT (18 weeks). Equal amounts 
(50μg) of each extract was used and confirmed by β-tubulin. (B) 
Absence of cleveage for procaspase 3 or PARP in AZT treated MT-2 
cells. (C) Senescence β-gal (SA-β gal) assay in MT-2 cells untreated 
and treated with AZT (18 weeks). A significant amount of 
senescence was detected only in end of cultures. (D) Western blots 
analysis of MT-2 cells treated with AZT. Samples were collected at 
different times after treatment from 0 to 15 weeks. Expression of 
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caspase 3, Bcl-2 and Bax was tested. Actin was used as loading 
control. (E) Western blots analysis of MT-2 cells treated with AZT. 
Samples were collected at different times after treatment from 0 to 15 
weeks. Expression of Tax was analyzed as described under materials 
and methods. Beta-tubulin was used to confirm equal loading. 
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Absence of procaspase-3 and PARP cleavage (Fig.2B) along with 
negative AnnexinV staining (data not shown), further confirmed the 
absence of apoptosis in AZT-treated HTLV-I cells. Instead, we found 
that HTLV-I cells undergo senescence as shown by the senescence β-
galactosidase assay, which was strongly positive in long term AZT 
treated MT-2 cells, but not in MT-2 control cells (Fig.2C). This was 
also confirmed in other treated HTLV-I cell lines (C10MJ, HUT102 
and LAF) (data not shown). 
 Analysis of samples collected at different intervals in MT-2 
cells cultured in the presence of AZT showed no significant 
differences in the levels of expression of apoptotic markers (Fig.2D). 
In contrast to previous observations made in HTLV-I infected cells 
treated with arsenic trioxide and IFN [25;26], the levels of the viral 
oncoprotein Tax remain unchanged during AZT treatment (Fig.2E).  
 
Continuing inhibition of telomerase by AZT in HTLV-I infected 
cells induces post transcriptional stabilization of p53. 
 
 To confirm these findings and gain further insights into the 
mechanisms involved, the expression level of p14ARF, a well known 
senescence marker [27], was analyzed. We found significant 
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increased expression of p14ARF in long term AZT-treated MT-2 cells 
(Fig.3A). Consistent with its ability to prevent Mdm2-mediated 
degradation of p53 [28], levels of p53 expression were considerably 
increased in AZT-treated cells when compared to control MT-2 cells 
(Fig.3A).  
 
Figure 3: Continuing inhibition of telomerase by AZT in HTLV-I 
infected cells induces post transcriptional stabilization of p53. (A) 
Western blot analysis for expression of p53 pathway regulators in 
untreated MT-2 and AZT-treated (18 weeks) MT-2 cells. Equal 
amounts (50μg) of each extract was used and confirmed by β-tubulin. 
(B) Analysis of p53 mRNA expression by RT-PCR in MT-2 and 
after culture with AZT for 18 weeks. GAPDH was used as internal 
control for amplification. (C) Western blot analysis of p53 after 24 
hours of AZT treatment. Equal amounts (50μg) of each extract was 
used and confirmed by β-tubulin. (D) Increased expression of p53 
detected by western blot in several HTLV-I infected cell lines (1185, 
C10MJ, LAF) treated for 4 weeks with AZT.  
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The underlying mechanism of increased p53 expression was post 
transcriptional, because the levels of p53 mRNA in MT-2 and AZT-
treated MT-2 cells remained similar (Fig.3B). In addition, the effect 
on p53 protein stabilization was only detected after long term 
treatment with AZT, and treatment with AZT for 24 hours did not 
result in any significant increase in the levels of p53 expression 
(Fig.3C). These results exclude a potential direct effect of AZT on 
p53 and suggest that telomere attrition plays an essential role in 
increasing the levels of p14ARF and p53 expression. Importantly, long 
term effects of AZT on cell cycle arrest and increased expression of 
p53 were reproduced in two independent experiments using MT-2 
and C10MJ cell lines, and were further confirmed in three other 
HTLV-I cell lines C10MJ, 1185 and LAF (Fig.3D), suggesting a 
general mechanism rather than an observation limited to MT-2 cells. 
Increased expression of p14ARF and p53 following long term AZT 
treatment was accompanied by an increase in Mdm2 expression 
(Fig.3A), and consistent with the previous findings that Mdm2 
promotes ubiquitination and proteasome degradation of MdmX [29], 
our results also revealed significant decrease in the levels of MdmX 
expression in long term AZT-treated MT-2 cells (Fig.3A). Thus, by 
blocking the ability of Mdm2 to target p53 for degradation, p14ARF 
causes p53 stabilization, and, by stimulating MdmX degradation by 
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Mdm2, p14ARF concurrently eliminates another inhibitor of p53 
function.  
Analysis of samples collected at different intervals in MT-2 cells 
cultured in the presence of AZT showed an increase in p53 
expression after 7 weeks of treatment and thereafter (data not 
shown). In contrast, in Jurkat cells treated in the same conditions, 
p53 levels of expression remained constant (data not shown). 
 
AZT triggers reactivation of p53-dependent transcription and 
accumulation of cyclin dependent kinase inhibitors p21waf and 
p27kip. 
 
 We hypothesized that the concerted actions of p14ARF, Mdm2 
and MdmX may lead to reactivation of p53 transcriptional activities. 
Previous studies have found that p53 is transcriptionally inactive in 
HTLV-I infected cells in vitro and in uncultured ATL cells, and that 
p53-responsive genes are not activated following ionization-radiation 
in these cells [30;31]. To test for reactivation of p53 transcriptional 
functions, long term AZT-treated MT-2 cells were subjected to mock 
or ionization-radiation, which produces DNA damage and induces 
transcription of p53 responsive genes. Our results confirmed the 
reactivation of p53 transcriptional activities, demonstrated by the 
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induction of p53-responsive genes p21WAF and Bax following 
ionization-radiation (Fig.4A). Spot densitometry indicated a 3.2 and 
1.8 fold increase for p21WAF and Bax mRNA expression following 
irradiation. Proliferation assays along with propidium iodide staining 
revealed that long term AZT-treated MT-2 cells arrest in all phases 
of the cell cycle (data not shown), a signature of cyclin-dependent 
kinase inhibitors (CDKI). Consistently, protein expression levels of 
both p21WAF and p27KIP were significantly increased following 
prolonged AZT treatment (Fig.4B).  
 
Figure 4: AZT-mediated reactivation of p53 functions and 
stabilization of CDKI p21WAF and p27KIP. (A) Expression of 
p21waf and Bax mRNA before and after ionizing radiation in AZT 
treated MT-2 cells (18 weeks). GAPDH was used as internal control 
for amplification. (B) Western blot analysis for expression of p21WAF 
and p27KIP in untreated MT-2 or after culture with AZT for 18 
weeks. Equal amounts (50μg) of each extract was used and 
confirmed by β-tubulin. (C) Analysis of p21WAF and p27KIP mRNA 
expression by RT-PCR in MT-2 and after culture with AZT for 18 
weeks. GAPDH was used as internal control for amplification. (D) 
Western blot analysis for expression of p27KIP in untreated MT-2 or 
after culture with AZT for 18 weeks, in absence or presence of 
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proteosome inhibitor Lactacystin. Equal amounts of each extract 
(50μg) were used and confirmed by β-tubulin. (E) MT-2 derived p53 
cDNA nucleotide sequence. (F) p53 amino acid sequence from MT-2 
cells compared to wild type p53. (G) RT-PCR for p53 responsive 
genes before and after gamma irradiation as described in the 
materials and methods. 
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Query: 1    catggaggagccgcagtcagatcctagcgtcgagccccctctgagtcaggaaacattttc 60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 251  catggaggagccgcagtcagatcctagcgtcgagccccctctgagtcaggaaacattttc 310 
                                                                         
Query: 61   agacctatggaaactacttcctgaaaacaacgttctgtcccccttgccgtcccaagcaat 120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 311  agacctatggaaactacttcctgaaaacaacgttctgtcccccttgccgtcccaagcaat 370 
                                                                      
Query: 121  ggatgatttgatgctgtccccggacgatattgaacaatggttcactgaagacccaggtcc 180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 371  ggatgatttgatgctgtccccggacgatattgaacaatggttcactgaagacccaggtcc 430 
                                                                         
Query: 181  agatgaagctcccagaatgccagaggccgctccccgcgtggcccctgcaccagcagctcc 240 
            ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct: 431  agatgaagctcccagaatgccagaggctgctccccgcgtggcccctgcaccagcagctcc 490 
                                                                        
Query: 241  tacaccggcggcccctgcaccagccccctcctggcccctgtcatcttctgtcccttccca 300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 491  tacaccggcggcccctgcaccagccccctcctggcccctgtcatcttctgtcccttccca 550 
                                                                        
Query: 301  gaaaacctaccagggcagctacggtttccgtctgggcttcttgcattctgggacagccaa 360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 551  gaaaacctaccagggcagctacggtttccgtctgggcttcttgcattctgggacagccaa 610 
                                                                        
Query: 361  gtctgtgacttgcacgtactcccctgccctcaacaagatgttttgccaactggccaagac 420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 611  gtctgtgacttgcacgtactcccctgccctcaacaagatgttttgccaactggccaagac 670 
                                                                         
Query: 421  ctgccctgtgcagctgtgggttgattccacacccccgcccggcacccgcgtccgcgccat 480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 671  ctgccctgtgcagctgtgggttgattccacacccccgcccggcacccgcgtccgcgccat 730 
                                                                         
Query: 481  ggctatctacaagcagtcacagcacatgacggaggttgtgaggcgctgcccccaccatga 540 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 731  ggccatctacaagcagtcacagcacatgacggaggttgtgaggcgctgcccccaccatga 790 
                                                                        
Query: 541  gcgctgctcagatagcgatggtctggcccctcctcagcatcttatccgagtggaaggaaa 600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 791  gcgctgctcagatagcgatggtctggcccctcctcagcatcttatccgagtggaaggaaa 850 
                                                                        
Query: 601  tttgcgtgtggagtatttggatgacagaaacacttttcgacatagtgtggtggtgcccta 660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 851  tttgcgtgtggagtatttggatgacagaaacacttttcgacatagtgtggtggtgcccta 910 
                                                                        
Query: 661  tgagccgcctgaggttggctctgactgtaccaccatccactacaactacatgtgtaacag 720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 911  tgagccgcctgaggttggctctgactgtaccaccatccactacaactacatgtgtaacag 970 
                                                                        
Query: 721  ttcctgcatgggcggcatgaaccggaggcccatcctcaccatcatcacactggaagactc 780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 971  ttcctgcatgggcggcatgaaccggaggcccatcctcaccatcatcacactggaagactc 1030 
                                                                         
Query: 781  cagtggtaatctactgggacggaacagctttgaggtgcgtgtttgtgcctgtcctgggag 840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1031 cagtggtaatctactgggacggaacagctttgaggtgcgtgtttgtgcctgtcctgggag 1090 
                                                                         
Query: 841  agaccggcgcacagaggaagagaatctccgcaagaaaggggagcctcaccacgaactgcc 900 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct: 1091 agaccggcgcacagaggaagagaatctccgcaagaaaggggagcctcaccacgagctgcc 1150 
                                                      
Query: 901  cccagggagcactaagcgagcactgcccaacaacaccagct 941 
            ||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1151 cccagggagcactaagcgagcactgcccaacaacaccagct 1191 
CLUSTAL W (1.82) multiple sequence alignment 
 
 
seq-p53WT_MT2_          MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP 60 
seq-p53WT_NM_000546_    MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP 60 
                        ************************************************************ 
 
seq-p53WT_MT2_          DEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 120
seq-p53WT_NM_000546_    DEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 120
                        ************************************************************ 
 
seq-p53WT_MT2_          SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE 180
seq-p53WT_NM_000546_    SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE 180
                        ************************************************************ 
 
seq-p53WT_MT2_          RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS 240
seq-p53WT_NM_000546_    RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS 240
                        ************************************************************ 
 
seq-p53WT_MT2_          SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP 300
seq-p53WT_NM_000546_    SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP 300
                        ************************************************************ 
 
seq-p53WT_MT2_          PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG 360
seq-p53WT_NM_000546_    PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG 360
                        ************************************************************ 
 
seq-p53WT_MT2_          GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD 393 
seq-p53WT_NM_000546_    GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD 393 
                        ********************************* 
+ +- -
p21WAFBaxGAPDH
+-
γ-irradiation
4E 4F
4G
 
 
However, while increased expression of p21WAF occurred at the 
transcriptional level (Fig.4C), presumably through p53, p27KIP 
mRNA expression remained comparable in MT-2 control and long 
term AZT-treated MT-2 cells suggesting a post transcriptional 
mechanism (Fig.4C). In fact, when MT-2 and AZT treated MT-2 
cells were incubated with lactacystin, a proteasome inhibitor; levels 
of p27KIP expression significantly increased in MT-2 but not in MT-2 
AZT treated cells (Fig.4D). These findings suggest that the p27KIP 
degradation pathway is hampered in long term AZT treated cells 
which allows for its stabilization. Our results are consistent with 
previous observations that limiting amounts of p27KIP correlate with 
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constitutive activation of the cyclin E-CDK2 complex and increased 
expression of p27KIP triggers cell cycle arrest [32]. We next 
confirmed that in the original MT-2 cells, p53 was wild type but 
transcriptionally inactive. To this end p53 cDNA was amplified, 
cloned and sequenced. As shown below we found three nucleotides 
changed in the p53 sequence from MT-2 cells (Fig.4E).  
However, these mutations were silent and did not affect the amino 
acid sequence which was wild type in MT-2 (Fig.4F). To confirm 
that p53 transcription was impaired we gamma-irradiated MT-2 cells 
and analyzed expression of p53-responsive genes bax and p21waf as 
reported in figure 4A. In clear contrast to AZT treated MT-2 cells, 
our results demonstrate that p53 is transcriptionally inactivated in 
untreated MT-2 cells (Fig.4G).  
 Overall our results suggest that prolonged AZT treatment and 
inhibition of telomerase activity leads to telomere attrition, restores 
p53’s functions, and increases expression of senescence markers 
p14ARF and p21WAF in long term AZT treated MT-2 cells. 
 
AZT based treatment induces telomerase inhibition and telomere 
shortening in vivo in ATL patients.  
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The effect of AZT in vitro requires several weeks of treatment [33], 
which parallels the slow kinetics observed in ATL patients treated 
with AZT (3). Strikingly, the estimated 30% failure rate of AZT 
treatment in HTLV-I infected ATL patients [34] coincides with the 
approximate percentage of ATL patients carrying a mutated inactive 
p53 gene [35]. These observations prompted us to investigate 
whether the effect of AZT in treatment of ATL patients also relied on 
telomerase inhibition, telomere attrition and p53 functions. 
 Samples were obtained from 18 ATL patients at different 
clinical stages, lymphomatous, smoldering, chronic and acute from 
two different origins (Necker hospital, France and NIH, USA). All 
samples were blind-tested and in each case the response to therapy 
was provided only after analysis. In the case of 3 ATL patients 
(ATL3, ATL4, ATL5) a paired sample, diagnostic and 
remission/relapse, could be obtained. Due to the intrinsic limitation 
in the amounts of each of the patient samples available, telomere 
sizes were measured by quantitative flow-FISH (Q-FISH) [36], 
before and after in vivo AZT treatment. To avoid potential variations 
between patient’s sample origins, we cell-sorted HTLV-I-infected 
from non-infected cells of three uncultured ATL patient samples 
collected prior to and after several weeks of AZT treatment and 
compared the relative telomere size in each cellular fraction. As 
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HTLV-I infected ATL cells over express the CD25 activation marker 
on their surface [37], we used anti-CD25-coupled magnetic beads to 
sort HTLV-I infected from their non-infected counterparts. 
Successful sorting was confirmed by staining each sorted cell 
population with an anti-CD25 fluorescein-isothiocyanate (FITC)-
conjugated antibody, and fluorescence-activated cell sorter scanner 
(FACS) analysis showed at least 95% purity (Fig.5A). 
 
Figure 5: Analysis of CD25+ HTLV-I infected cells. (A) FACS 
analysis of the presence of CD25 marker expression from CD25+ 
and CD25- sorted cells. (B) Telomerase activity detected by TRAP 
assay in CD25+ and CD25- fractions isolated from an HTLV-I- 
donor and ATL PBMCs. (C) Integrated HTLV-I proviral DNA was 
detected by PCR using primers in the tax coding region. GAPDH 
was used as amplification control to ensure proper quality and 
quantity of extracted DNAs. (D) Staining control of PBMCs in 
presence or absence of FITC-telomere probe. (E) In situ 
hybrizidation of FITC-conjugated telomere probe (top) and DAPI 
(bottom). 
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 To ensure that CD25+ sorted cells correspond to HTLV-I infected 
cells and not uninfected CD25+ regulatory T-cells (Tregs), CD25+ 
and CD25- cells isolated from PBMCs of a healthy individual and 
those of an ATL patient were tested by TRAP assay. Significant 
telomerase activity was only detected in the CD25+ population 
isolated from the ATL patient and no or very low telomerase activity 
was detectable in either population isolated from the non-HTLV-I 
infected donor (Fig.5B), suggesting that Tregs are mostly telomerase 
negative and that the CD25+ cell fraction isolated from the ATL 
patients indeed corresponds to HTLV-I infected cells.  In fact, 
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integrated HTLV-I provirus was detected by PCR in CD25+ cells 
isolated from the ATL patient only (Fig.5C). Specific hybridization 
of the FITC- labeled probe to the telomeric ends was confirmed by 
microscopic observation of a punctuated pattern consistent with 
telomere labeling (Fig.5D and 5E). 
 
Telomerase activity was readily detected by TRAP assay in all tested 
ATL patients (data not shown). Treatment with AZT reduced 
telomerase activity in vivo (Fig.6A).  
 
Figure 6: AZT-induced telomerase inhibition and telomere 
shortening in ATL patients. (A) Inhibition of telomerase activity 
measured by TRAP in vivo ATL patients before and during treatment 
with AZT. (B) FACS analysis of telomere size by Flow-FISH in 
CD25+ and CD25- cells isolated from uncultured ATL patient 
samples. (C) Average telomere size in CD25+ cells before and after 
AZT treatment calculated from two independent measurements. (D) 
Detection of exon 1 and 2 of the p14ARF gene by PCR in CD25+ cells 
from two ATL patients before AZT treatment or after AZT 
treatment, GAPDH amplification was used as control. (D) diagnosis, 
(R) relapse/death, (CR) complete remission. (E) Detection of 
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provirus integration site by inverse PCR before and after AZT 
treatment, (D) diagnosis, (R) relapse.  
 
 
While average telomere size from CD25- cells was not affected by 
treatment with AZT, a 14% to 30% reduction in telomere length 
occurred in HTLV-I infected CD25+ cells after treatment with AZT 
(Fig.6B and 6C). Since p14ARF is an important player in p53 
functions and overlaps the p16ink locus, a gene frequently 
methylated, deleted or mutated in ATL patients [38-41], we analyzed 
the integrity of the p14ARF gene. At the time of diagnosis p14ARF 
exons1 and 2 were present in ATL5 patient, but p14ARF exon 2 was 
deleted in HTLV-I infected cells of ATL4 patient (Fig.6D). 
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However, a recent study showed that exon 2 is dispensable for 
p14ARF function and the amino-terminal 29 residues of p14ARF are 
sufficient for stabilization of p53 [42]. Interestingly, analysis of the 
ATL4 patient’s DNA revealed the presence of both p14ARF exons 
after the course of AZT treatment and patient disease relapse 
(Fig.6D). These findings suggest that in patient ATL4, treatment with 
AZT eradicated the initial tumor clone but resulted in the outgrowth 
of a different tumor clone at relapse. In fact, inverse PCR 
experiments and sequencing demonstrated a different provirus 
integration site in ATL4 patient’s DNA samples collected at 
diagnostic and after disease relapse (Fig.6E).  
 
Response of ATL patients to AZT based therapy correlates with 
their p53 transcriptional status. 
 
 As most mutations that inactivate p53-dependent transcription 
lead to protein stabilization, we investigated p53 stabilization by 
immunochemistry in four ATL patients. Many studies have reported 
stabilization and increased expression of transcriptionally inactive 
mutated p53. In three patients that did not respond to AZT treatment 
p53 expression was readily detectable by immuno histochemistry 
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(Fig.7A). In contrast, in patient responding to AZT, p53 expression 
was very weak, consistent with a wild type p53 sequence (Fig.7A).  
 
Figure 7: Response of ATL patients to AZT based therapy 
correlates with their p53 transcriptional status. (A) Immuno-
histochemistry detection of p53 expression in ATL samples collected 
from AZT responder (top) and non responders (bottom) performed as 
previously described 3. (B) p53 from ATL patients was cloned into 
pCDNA3.1 and tested in a functional assay. Jurkat T-cells were 
transfected with a p53-responsive vector and p53 expression vectors 
and luciferase activity detected 24 hours later. Results are 
representative of two independent experiments.  
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In order to establish a correlation between the p53 status and the 
outcome of ATL patients that received AZT therapy the p53 hot spot 
region, exon 4 through 9, was cloned by RT-PCR. In each case, we 
sequenced two p53 hot spot clones from 14 ATL patients. For ATL3, 
4 and 5; two p53 hot spot clones were sequenced both from before 
treatment and after remission/disease relapse. Whenever the p53 hot 
spot region was found to be wild type in sequence, the whole p53 
cDNA was then cloned and two additional clones were sequenced to 
confirm the phenotype. 
 Our results demonstrate that all ATL patients carrying a wild 
type p53 gene responded to AZT treatment and went into partial or 
complete remission (Table 1). In contrast, all patients carrying a 
mutated p53 at diagnosis did not respond to AZT treatment and died 
within a short period of time (Table1). Thus, a total correlation 
between p53 and AZT response was found and makes the results 
highly significant. 
The biological relevance of our finding is further supported in the 
case of ATL4, in which the initial response to treatment was 
associated with the presence of a wild type p53, but as indicated 
above, AZT treatment led to the selection of another tumor clone and 
disease relapse. Strikingly, the clone responsible for the relapse 
carried a p53 mutated at R273H, a well characterized mutation that 
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abrogates p53 transcriptional activities. All p53 mutations of 
unknown function were further tested in a luciferase functional 
reporter assay after transfection in Jurkat T-cells (Fig.7B).  
Results confirmed an absolute correlation between the p53 
transcriptional status and the response of ATL patients to AZT 
treatment (Table1 and Fig.7B). 
 
Table 1: Correlation between AZT treatment response and p53 
status in ATL patients.  Status of patients before AZT treatment, 
response to treatment, status of p53 gene and its transcriptional 
activity. The criteria for clinical therapeutic response were as 
follows: complete remission (CR) was defined as the disappearance 
of all measurable and assessable disease lasting more than 3 month; 
partial remission (PR) was defined as reduction of leukemic cell 
count lasting more than 1 month but less than 3 months; not 
responding (NR) was defined as increase in leukemic cell count. 
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 DISCUSSION: 
 
 Results described here provide a novel link between 
telomerase targeting, telomere attrition and reactivation of p53-
dependent senescence pathways in HTLV-I infected cells. While it is 
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established that p53 is inactive in HTLV-I infected cells, the 
molecular mechanism of p53 transcriptional inactivation remains a 
matter of debate [43-49]. Our results clearly indicate that the p53 
inactivation mechanism is reversible and could therefore be used to 
develop novel therapeutic interventions. Previous studies have shown 
that localization and DNA-binding activity of p53 is not altered in 
HTLV-I cells, and it is more likely that post transcriptional 
modification and/or association with specific cellular partners 
dictates the inhibition. Whether prolonged action of AZT modulates 
the phosphorylation or the acetylation status of p53 or its interaction 
with cellular partners warrants further studies. 
Results obtained from patient ATL 4 further underscore the 
importance of a functional p53 (Fig.6 and Table 1). Initial responses 
to AZT treatment coincides with the presence of a major tumor clone 
that is wild type p53 in sequence. Eradication of that tumor clone 
however led to the emergence of a minor clone carrying a mutated 
and inactive p53. This selection also coincides with disease relapse 
and death of the patient. Analyses of the p14ARF locus and the 
provirus integration sites, at the initiation of treatment and at disease 
relapse, clearly indicate that the two tumor clones present in this 
patient are distinct.  
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Several studies have found that TGF-beta signaling is impaired in 
HTLV-I infected cells in vitro and in ex vivo ATL patient samples 
[50-52]. Since prolonged treatment of HTLV-I cells with AZT 
reduces MdmX protein expression which has been implicated in 
inhibition of Smad transactivation and TGF-beta signaling [53;54] 
we tested whether this pathway may be reactivated. However, 
transfection of MT-2 and AZT treated MT-2 cells with a TGF-beta 
reporter vector in the absence or presence of exogenous TGF beta did 
not show any difference in activity (data not shown), suggesting that 
either MdmX is not involved in TGF-beta inhibition or at least that 
down-regulation of MdmX is not sufficient to restore TGF-beta 
signaling in HTLV-I transformed cells.  
 Interestingly, a recent study reported complete response and 
suppression of HTLV-1 viral load following Alemtuzumab therapy 
in AZT/IFN refractory adult T-cell leukemia[55]. Since 
Alemtuzumab is active in a mouse model of ATL [56] and in patients 
with refractory T-cell malignancies or CLL with mutated or absent 
p53 gene [57;58] it could be used in combination or in maintenance 
treatment to prevent emergence of p53 mutated clones in patients 
responding to AZT therapy. It should be noted that the majority of 
ATL are wild type p53 and die of their disease despite of AZT/IFN 
or other treatments. In this study we did not use IFN-alpha because 
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AZT has been shown to have some effect on its own in several virus-
associated hematological disorders and to limit the number of 
variable parameters and facilitate analysis. However, synergies 
previously observed in vivo between AZT and IFN-alpha may in part 
result from the transcriptional inhibition of the hTERT promoter by 
IFN-alpha as significant down regulation of hTERT mRNA 
expression and telomerase activity has been reported in leukemic cell 
lines as well as in primary leukemic cells 35. It is also possible that 
additional functions of IFN- alpha may be involved.  
 Our study identifies p53 status as an essential predictive 
marker for the response of HTLV-I infected ATL patients to 
AZT/IFN treatment and suggests that such therapy may not have any 
clinical benefits in patients carrying a mutated, inactive p53 gene for 
which alternative therapies such as allogenic bone marrow transplant, 
Alemtuzumab or radio-immunotherapy for IL-2Rα [59;60] should be 
considered. Patients treated with chemotherapy or radiotherapy 
usually select for tumor clones with mutated p53 and become non 
responders to AZT when used in the second line of treatment [34]. 
We propose that for patients carrying wild type p53, AZT/IFN 
should be considered as the first line of treatment. Whether the effect 
of AZT/IFN on AIDS-related Kaposi sarcoma, Kaposi sarcoma 
associated primary effusion lymphoma and AIDS-related primary 
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central nervous system lymphoma in vivo is also p53-dependent, is of 
significant importance and warrants further investigations. In 
addition, it is possible that other human cancers, such as HPV-
associated cervical cancer or breast carcinomas, for which p53 
remains wild type may benefit from AZT/IFN therapy deserve to be 
considered. 
 
MATERIALS AND METHODS:  
 
Cell culture:  
HTLV-I cell lines were maintained in RPMI 1640-10% FBS with 
and without IL-2. Cells were treated with 50 μM AZT or 10 μM 2’, 
3’-Dideoxyguanosine, ddG (CalBiochem, La Jolla, CA). Medium 
containing AZT or ddG was replaced every 3 days until growth 
arrest.  
Patients:  
Samples were obtained after informed consent and in agreement with 
regulations for the protection of human subjects according to the NIH 
guidelines. Treatment regimens AZT and IFN were previously 
reported 3,4. Clinical status of the patients and response to AZT 
treatment is reported in table 1. Patients 2 and 7 were initially treated 
with chemotherapy (CHOP) while patients 13 and 14 received 
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yttrium-90 monoclonal antibody therapy. All other patients received 
AZT therapy combined with IFN- α as a first line of treatment. PR 
refers to when ATL cells were still detectable by FACS analysis 
(>5%) while CR means no detectable ATL cells by FACS in the 
peripheral blood. 
TRAP assay:   
Telomerase activity was measured by TRAP assay using Trapeze 
Telomerase detection kit (Chemicon, Temecula, CA) followed by 
SYBR-green staining (Molecular Probes, Eugene, OR) and 
quantified as previously reported 18. An equal amount of protein 
lysates in CHAPS buffer was used. Results are representative of 
three experiments. 
Telomere length analysis:  
Genomic DNA was isolated and telomere length was determined by 
Southern blot analysis using TeloTAGGG telomere length assay kit 
(Roche, Indianapolis, IN) according to manufacturers’ instructions. 
Flow Q-FISH:  
Peripheral CD25+ T-cells were isolated from HTLV-I infected ATL 
patients using anti-CD25 magnetic Dynabeads (Dynal Biotech, Lake 
Success, NY). The telomere length of CD25+ cells from different 
patients were quantitatively determined by hybridization of Telomere 
PNA /FITC probe by flow cytometry (FACSCalibur, Becton 
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Dikinson, San Jose, CA) using Telomere PNA /FITC kit  
(DakoCytomation, Carpinteria, CA) as reported [61] and according 
to manufacturer’s instructions. 
Western blots:  
Equal amounts of proteins from untreated and long-term AZT-treated 
MT2 cells were resolved by SDS-PAGE. All primary and secondary-
HRP conjugated antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Bax (N-20), Bcl-xL(H-62), Mcl-
1(S-19), Bcl-2 (N-19), PARP (H-250), caspase-3 ( H-277), p14ARF 
(FL-132), p53 (FL-393), MDM2 (SMP-14), MDMX (D-19), p21WAF 
(C-19), p27KIP (C-19G), and β-tubulin (D-10) was used as loading 
control.  
Senescence β-gal (SA-β gal) assay:   
Untreated and long term AZT-treated MT2 cells were fixed in 2% 
formaldehyde-0.2% glutaraldehyde for 3 min, washed with PBS and 
incubated at 37°C with SA-β-gal staining solution, pH 6.0. Images 
were captured using a Nikon EFD3 microscope (Boyce Scientific, St 
Louis, MO) and Nikon camera with an Eplan 100X (160/0.17) 
objective. Acquisition software, Image-ProExpress version IV was 
from Media Cybernetics (Silver Spring, MD).  
PCR and Semi-quantitative RT-PCR:  
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RT-PCR primers were as the following: p53 – forward primer F: (5′-
GTCCCCGGACGATATTG-3′), reverse primer R:(5′-
CCAGAATGCAAGAAGCCCAG-3′); p21WAF F:(5′-
GAAGAAGGGTAGCTGGGGCT -3′), R:(5′- 
CTCTAAGGTTGGGCAGGGTG -3′); p27KIP F:(5′ 
TGCCCGAGTTCTACTACAGACC-3′), 
R:(5′CTTATTCCTGCGCATT 
GCTCCGC -3′); Bax F: (5´-GGGGACGAACTGGACAGTAA – 3´), 
R:(5´CAGTTGAA 
GTTGCCGTCAGA-3´); p14ARF exon1 F: (5´- 
CTGGAGGCGGCGAGAACATGG -3´), R: (5´- 
GGGCCTTTCCTACCTGGTCTT- 3´); p14ARF exon2 F: (5´- 
GCTCTACACAAGCTTCCTTTCCG-3´), R: (5´- 
CGGGCTGAACTTTCTGTGCTGG -3´) and GADPH F: (5´-
GAAGGTGAAGGTCGGAGTC -3´), R: (5´-
GAAGATGGTGATGGGATTTC-3´). Total RNA was isolated by 
Trizol reagent (Invitrogen, Carlsbad, CA) and RT-PCR was 
performed using the One-Step RT PCR kit (Qiagen, Valencia, CA).  
Inverse LTR-PCR:   
Proviral integration site was determined by digesting genomic DNA 
by SmaI, ligation and inverse PCR with HTLV-I LTR primers F: (5´- 
CCCCAAATATCCCCCGGG-3´) and R: (5´- 
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GGGGCTTATGGTCATTGTC- 3´). The amplified products were 
cloned into pCR2.1 TA vector (Invitrogen, Carlsbad, CA) and 
sequenced. 
p53 status and functional assay:  
Total RNA was isolated from ATL patients and the p53 hotspot 
region was amplified by RT-PCR using the following primers F: 5´-
CCAGAAAACCTACCAGGGCAG -3´, R: 5´-
GCTCGCTTAGTGCTCCCTGG-3´, cloned and sequenced. For p53 
full length RT-PCR and cloning we used F: 5’-
CGGAATTCATGGAGGAGCCGCAGTCAGATCC-3’ and R: 5’-
CCGCTCGAGTCAGTCTGAGTCAGGCCCTTCTG-3’. For the p53 
functional assay, the p53 from MT-2 (wild type) was cloned into 
pcDNA3.1Zeo vector (Invitrogen, Carlsbad, CA) and the hotspot 
region from pcDNAp53MT2 was substituted by respective ATL p53 
hotspot regions using DrdI-BsaI restriction enzymes.  Luciferase 
assays were performed with Luciferase Reporter Assay kit (Promega, 
Madison, WI) by transfecting Jurkat E-6 cells with p53-responsive 
pGL13Luc and respective ATL pcDNA3.1Zeo-p53.   
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Regulation of Telomerase and Telomeres: 
Human TumorViruses Take Control. 
 
 
ABSTRACT:   
Human tumor viruses are responsible for one-fifth of all cancers 
worldwide. These viruses have evolved multiple strategies to evade 
immune defenses and to persist in the host by establishing a latent 
infection. Proliferation is necessary for pre-tumor cells to accumulate 
genetic alterations and to acquire a transformed phenotype. However, 
each cell division is associated with a progressive shortening of the 
telomeres, which can suppress tumor development by initiating 
senescence and irreversible cell cycle arrest. Therefore, the ability of 
virus-infected cells to circumvent the senescence program is 
imperative for the long-term survival/ proliferation of infected cells 
and the likelihood of transformation. We review the multiple 
strategies used by human DNA and RNA tumor viruses to subvert 
telomerase functions during cellular transformation and 
carcinogenesis. Epstein-Barr Virus, Kaposi Sarcoma-associated 
Herpes Virus, Human Papillomavirus, Hepatitis B Virus, and Human 
T-cell Leukemia Virus-I each can increase transcription of the 
telomerase reverse transcriptase.  Several viruses appear to mediate 
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cis-activation or enhance epigenetic activation of telomerase 
transcription. Epstein-Barr Virus and Human Papillomavirus have 
each developed post-transcriptional mechanisms to regulate the 
telomerase protein. Finally, some tumor virus proteins can also 
negatively regulate telomerase transcription or activity.  It is likely 
that, as future studies further expose the strategies used by viruses to 
deregulate telomerase activity and control of telomere length, novel 
mechanisms will emerge and underscore the importance of increased 
telomerase activity in sustaining virus-infected cells and its potential 
in therapeutic targeting.   
 
INTRODUCTION: 
 
Telomeres, which form the ends of eukaryotic chromosomes, 
are composed of tandem arrays of telomeric repeats (5'-TTAGGG-3' 
in humans) and help to preserve genome integrity and to prevent 
senescence (1,2). Somatic cells have a finite proliferative capacity, 
due largely to the inability of DNA polymerase to replicate the distal 
ends of chromosomes, leading to a progressive shortening of the 
telomeres after each cell division. Immortal tumor cells overcome 
this barrier mainly by increasing transcription of telomerase, a 
cellular reverse transcriptase that can extend telomeric ends (3-5).  
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Increased telomerase activity may contribute indirectly to the 
transformation process by sustaining the proliferation of pre-tumoral 
cells indefinitely, thereby increasing the potential risk of cumulative 
genetic defects. Only 10% of human tumor cells do not express 
telomerase; these cells use an alternative lengthening of telomeres 
pathway, referred to as ALT, to maintain telomere length. (6) Recent 
studies show that the ALT pathway involves the DNA repair and 
homologous recombination machinery (7,8).  Telomerase is a 
holoenzyme that consists of several subunits, including hTR (human 
telomerase RNA), TEP1 (telomerase associated protein1), hTERT 
(human telomerase reverse transcriptase), hsp90 (heat shock protein 
90), p23, and dyskerin (1).  The ability of telomerase to extend 
telomere length is complex.  Not only is the hTERT gene subject to 
transcriptional, post-transcriptional, and epigenetic control, but 
access of telomerase to the telomere ends is also regulated by the 
shelterin complex.  Shelterin consists of the double-stranded DNA 
binding proteins, TRF1 and TRF2 (TTAGGG repeat binding factors -
1 and -2), the single-stranded DNA binding protein, POT1 
(protection of telomere), and their binding partners, TIN2 (TRF1-
interacting nuclear protein 2) and PTOP (POT1- and TIN2-
interacting protein) (9).  Shelterin provides telomerase with 
stochastic signals regarding the length of telomeres, which then 
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allows or prevents telomerase from gaining access to the telomere 
ends.  In addition, the shelterin components can form various 
subcomplexes that determine the structure of the telomere ends and 
preserve the integrity of telomeres by preventing DNA damage 
pathways from becoming activated (10).     
Although telomere attrition can lead to chromosomal 
abnormalities, a direct role for telomeres or telomerase in the 
transformation process is not likely. Somatic cells expressing 
telomerase can extend their replicative lifespan but are unable to 
form tumors in nude mice and do not form colonies in soft agar (11). 
By contrast, normal epithelial and fibroblast human cells can be 
converted to tumorigenic cells with expression of transfected hTERT 
and Ras oncoproteins along with the large T-antigen of simian virus 
40 (SV40) (12). Removal of SV40 proteins from normal human 
somatic cells could still lead to transformation as long as Rb and p53 
were inactivated and Ras, c-Myc, and hTERT were overexpressed 
(13). Taken together, these findings suggest that overexpression of 
telomerase by itself is not sufficient to induce a tumorigenic state in 
normal cells, but it can contribute to tumorigenesis in the presence of 
additional oncogenes and/ or the disruption of tumor suppressors.  
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OVERVIEW OF TELOMERASE ACTIVITY AND 
TELOMERE LENGTH IN HUMAN ONCOGENIC VIRUS 
INFECTIONS: 
 
Epstein-Barr Virus (EBV) 
 EBV infection is associated with Burkitt lymphoma, Hodgkin 
disease, nasopharyngeal carcinoma, and infectious mononucleosis, 
along with approximately 10% of gastric cancers and a subset of T-
cell lymphomas (14). EBV mainly infects and immortalizes B-
lymphocytes, but it can also produce latent infections in T-
lymphocytes or natural killer cells. Analysis of samples from patients 
with nasopharyngeal carcinoma revealed that 94.9% were positive 
for telomerase activity, and analysis of EBV-immortalized B-
lympboblastoid cell lines revealed increased telomerase activity, both 
supporting an important role for telomerase reactivation in EBV-
infected individuals (15,16).  
  The EBV-encoded latent membrane protein-1 (LMP1) 
displays properties of a constitutively active member of the TNF 
receptor family. LMP1 is expressed during viral latency leading to 
the activation of NF-kappaB and Jak/STAT signaling pathways and 
oncogenic transformation (17). LMP1 is at least partially responsible 
for the increase in telomerase activity in nasopharyngeal epithelial 
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cells (18).  LMP-1 also appears to enhance telomerase activity in B-
cell lymphomas, in which expression of small interfering RNAs 
(siRNAs) directed against LMP1 substantially reduced hTERT 
protein levels and telomerase activity (19). Moreover, expression of 
LMP1 in an EBV-negative nasopharyngeal carcinoma cell line 
increased hTERT protein expression (19). Although hTERT has not 
been implicated in regulation of gene expression, a recent study 
suggests that hTERT expression decreases EBV lytic gene 
expression and promotes proliferation of latently infected B-
lymphocytes (20).   Other work in B-lymphoblasts suggests that 
immortalization may be associated with the reactivation of 
telomerase activity, along with aneuploidy and changes in p16, Rb, 
and p53 status; however, this finding has yet to be confirmed by 
independent laboratories (21,22).  
EBV latent membrane protein 2A (LMP2A) induces 
constitutive activation of downstream effectors of the B-cell receptor, 
preventing infected cells from entry into the lytic replication cycle 
(23). LMP2A is also involved in transformation of epithelial cells. 
Transient transfection assays indicate that LMP2A may act as a 
negative regulator of the hTERT promoter (24). 
Analysis of telomere lengths in EBV-positive Burkitt’s 
lymphoma cell lines showed increases in telomere length compared 
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with that in EBV-negative cells (25,26). Although infections by 
many tumor viruses have been associated with increased telomerase 
activity, EBV is, to date, the only human oncogenic virus for which 
infection has been linked to an actual increase in telomere length.  
 
Human Herpes Virus 8/ Kaposi Sarcoma–associated Herpes 
Virus (HHV-8/ KSHV) 
 HHV-8/ KSHV is the etiologic agent for Kaposi’s sarcoma, 
multifocal Castleman’s disease, and primary effusion lymphoma 
(27).  KSHV-transformed endothelial cells have elevated telomerase 
activity compared with uninfected cells (28). The latency-associated 
nuclear antigen (LANA) protein of HHV-8/ KSHV plays an 
important role in latent episomal persistence of the viral genome in 
infected cells (29). LANA targets p53 and Rb and plays a role in B-
cell lymphoma development (30). LANA has been found to increase 
hTERT promoter expression through modulation of Sp1 in 
fibroblasts 293, and B-cell lines BJAB and BCBL1 cells (31,32).  
 To date, the influence of infection on telomere length in 
HHV-8/ KSHV-infected cells has not been reported. However, it has 
been shown that an angiogenic lytic gene, the G protein–coupled 
receptor oncogene (vGPCR), of KSHV can immortalize human 
umbilical vein endothelial cells (HUVEC) in which telomere length 
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was maintained by the ALT pathway (33). A direct oncogenic role 
for vGPCR has not been established as it is an early lytic gene not 
expressed in HHV-8/ KSHV transformed cells.  
 
Human Papillomavirus (HPV) 
 Over 100 types of HPV are responsible for a wide array of 
human diseases, ranging from malignant cervical cancer to benign 
warts (34). High-risk HPV16 and 18 are the genotypes most 
commonly associated with cancer (35,36).  
Early studies with HPV16 found elevated telomerase activity 
in pre-crisis human cervical keratinocytes (HCKs) that express the 
viral protein E6 (37). HPV E6 cooperates with E7 to transform 
infected cells by targeting p53 and Retinoblastoma (Rb) for 
proteasomal degradation, respectively (38).  
Further studies indicated that E6-mediated elevation of 
telomerase activity requires an additional protein, the E6-associated 
protein (E6AP) (39). E6AP is an ubiquitin-ligase that is involved in 
p53 degradation. Because E6AP is also involved in ubiquitination, it 
has been suggested that E6 targets a cellular inhibitor of telomerase 
activity for degradation using the ubiquitin machinery that is also 
used to degrade p53. A recent study demonstrated that E6 mutants, 
defective in E6AP binding retained their ability to stimulate hTERT 
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expression, (40) suggesting the existence of both E6AP-dependent 
and -independent mechanisms for E6-mediated increase in hTERT 
expression.   
HPV16 E6-expressing fibroblasts had an increased lifespan 
and did not enter cellular senescence, unlike control cells that also 
had a marked decrease in telomere length (41).  In these E6-
expressing cells, the shortened length of the telomeres was eventually 
stabilized through an ill-defined mechanism.  
A similar pattern—i.e., increased telomerase activity 
following viral infection and telomere shortening followed by 
stabilization—is found in HPV-infected cells, as in  nearly all human 
infections by oncogenic viruses.  For example, analysis of patient 
samples from early stages of cervical intraepithelial neoplasia to 
later, malignant stages of this disease demonstrated the persistence of 
shortened telomeres and strong telomerase activity in all stages of 
disease (42).   
HPV early gene E2 is important for viral transcription 
through E2 responsive elements and replication (43). E2 can also 
suppress growth of HPV-positive cancer cells through transcriptional 
repression of E6 and E7 (44). Since E6 is a positive regulator of the 
hTERT promoter, it is expected that E2 would act as a negative 
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regulator in the context of HPV infected cells by preventing the 
action of E6. 
 
Hepatitis B and Hepatitis C Virus (HBV/HCV) 
  HBV and HCV infect hepatocytes, leading to chronic liver 
disease and malignant transformation. Combined, they account for 
70% of hepatocellular carcinomas worldwide (45).  Tissue biopsies 
from HBV-positive patients exhibited strong telomerase activity 
compared with those from normal liver tissue, irrespective of disease 
stage (46). Short telomeres were present in HBV- and HCV-positive 
tissues despite elevated telomerase activity (47). Similarly, telomeres 
have been found to be shorter in hepatocellular carcinoma than in 
non-cancerous liver tissues isolated from the same patient (48,49).  
HBV encodes two proteins with transcriptional activator 
functions – the HBV-X and preS2 activators (large surface proteins 
and truncated middle surface proteins) (50). The HBV-X 
transactivator oncoprotein (HBx) stimulates viral gene expression 
and cellular transformation by altering p53 functions and disrupting 
multiple cell signaling pathways (51). HBx has been shown to 
increase telomerase expression and telomerase activity in hepatoma 
cells (52).   Transfection of the preS2 gene into a hepatocellular 
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carcinoma cell line was also associated with an increase in 
telomerase expression and activity (53). 
 
Human T-cell leukemia virus type 1 (HTLV-I) 
 HTLV-I is the etiological agent of adult T-cell 
leukemia/lymphoma, a lymphoproliferative disorder of infected 
CD4+ T-cells (54). Similar to the pattern seen in HPV, HBV, and 
HCV infections, telomeres are short in HTLV-I infected cells despite 
the presence of strong telomerase activity (55). Telomerase activity 
was high in both HTLV-I-immortalized and HTLV-I-transformed 
cell lines as well as lymphocytes from patients with adult T-cell 
leukemia/lymphoma, including those with acute, smoldering and 
chronic disease, compared with peripheral blood mononuclear cells 
from uninfected individuals or samples from asymptomatic carriers 
(55-57). Disease progression, from the asymptomatic stages to acute 
and chronic disease, was correlated with increased telomerase 
activity, such that patients with acute and chronic disease exhibit a 
higher level of telomerase activity than asymptomatic carriers of the 
virus (55,57). Multiple other studies have confirmed that HTLV-I 
infected cells have elevated telomerase activation (58,59). Additional 
studies found that increased telomerase activity was not correlated 
with transformation status as measured by IL-2 dependence (55).  
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A direct role for HTLV-I in the elevation of hTERT 
expression was demonstrated by in vitro transmission of the virus to 
human primary T-cells (60), which led to increased hTERT promoter 
expression in infected cells only. Similar results were obtained by 
transduction of lymphocytes with a Tax-expressing vector. Although 
a study proposed that the HTLV-I-encoded Tax protein had a 
negative effect on an hTERT promoter reporter vector in transient 
assays (61), current data indicate that Tax is a strong positive 
regulator of the endogenous hTERT promoter (60,62).  
The initial report that Tax acts as a repressor of the hTERT 
promoter turned out to be misleading because these experiments 
were performed in the presence of phytohaemagglutinin (PHA), a 
potent inducer of hTERT expression. Results showed that PHA-
mediated induction of hTERT was indirectly lessened by Tax, 
however such effects were not seen when Tax was expressed in the 
absence of PHA stimulation. Thus, Tax should be considered as a 
positive regulator of the hTERT promoter. It remains to be 
demonstrated whether, in the context of HTLV-I infected cells, Tax 
prevents full induction of hTERT expression in physiological 
conditions which trigger cell activation (PHA or antigen stimulation),     
 
Model  for Telomere Maintenance in Virus-Infected Cells. 
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A list of the tumor virus-encoded regulators of telomerase 
activity that we have described is presented in Table 1. 
Table 1:  Human tumor virus-encoded regulators of telomerase 
activity. 
Viral-encoded Regulator Impact on Telomerase 
EBV A)  LMP1
B)  LMP2A
A)  Positive
B)  Negative
HHV-8 A)  LANA A)  Positive
HPV A)  E6
B)  E6AP
C)  E2
A)  Positive
B)  Positive (through NFX1-123)
Negative (through NFX1-91)
C)  Negative
HBV A)  HBX A)  Positive
HCV A)  HCV-C A)  Positive
HTLV-1 A)  Tax A)  Positive
 
 
Current data support a model in which the initial stages of 
viral infection are associated with progressive telomere shortening 
despite an increase in hTERT expression (Fig. 1).  
 
Figure 1: During most oncogenic viral infections, enhanced 
replication leads to a state of progressive telomere shortening, which 
if unchecked, promotes senescence/apoptosis of the infected cells.  
Oncogenic viruses protect infected cells with critically short 
telomeres by overexpressing telomerase, which can maintain 
telomere length.  In this model, chromatin bound genomic DNA 
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(light blue) is protected by telomeres (white bar) bound by shelterin 
sub-complexes (light purple).  Telomerase (dark blue) is either A. 
unable to elongate telomeres due to structural hindrance (black loop), 
or B. unable to elongate telomeres due to the presence of a negative 
telomerase regulator(s) (green), and/or the absence of a positive 
telomerase recruiter(s) (red).  Critically short telomeres can lead to 
disruption of the structural interference or loss of the negative 
regulator(s), thereby allowing telomerase access to the telomere ends.  
Alternatively, critically short telomeres may signal the recruitment of 
a positive regulator(s), which delivers telomerase to telomeres.  In 
this model, telomeres remain short in viral-infected cells, which are 
protected from senescence/apoptosis by the overexpression of 
telomerase.  Telomerase can then maintain the shortened telomere 
length during each successive replication cycle and aid in 
establishing an oncogenic state.   
Light blue:  chromatin, white bar:  telomeres, light purple:  shelterin, 
dark blue:  telomerase, red:  negative telomerase regulator, green:  
positive telomerase regulator. 
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Shortened telomere lengths are eventually stabilized, and 
maintenance of telomere size becomes dependent on elevated 
telomerase activity (55). The reasons for the initial telomere 
shortening and stabilization are unclear. Variations in the 
composition of the shelterin complex or accessibility of telomerase to 
the telomeres may explain this phenomenon and warrant further 
studies. The presence of shortened telomere and aneuploidy in cancer 
cells are circumstantial, and to date, there is no experimental 
evidence that telomere attrition induces chromosome instability.    
In some instances, short telomeres may be poor prognosis 
makers for disease progression, as is the case in hepatocellular 
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carcinoma and several leukemias, including chronic myeloid 
leukemia, chronic lymphocytic leukemia, and HTLV-I associated 
adult T-cell leukemia/lymphoma (63-66). However, in other types of 
cancer, such as HPV-associated cervical cancer, there is no obvious 
relationship between telomere length and the clinical outcome (67).  
Although telomeres were substantially shortened in all cervical 
intraepithelial neoplasia samples, no further telomere shortening 
occurred in the majority of samples from patients during transition to 
a malignant phenotype (42). 
 
MECHANISMS OF VIRAL ACTIVATION OF 
TELOMERASE: 
 
  hTERT expression is regulated primarily at the level of 
transcription (68).  The hTERT promoter contains several E-boxes 
and five GC-rich elements, which can bind c-Myc and Sp1, 
respectively (69). It is well established that hTERT gene expression 
is increased following c-Myc binding to E-box elements present in 
the hTERT promoter (70,71).  In fact, in most cells, c-Myc and Sp1 
act cooperatively as the dominant determinants of hTERT expression 
(69,72).   A more complete listing of various factors known to 
regulate hTERT transcription can be found in Table 2.  The most 
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important tumor virus proteins, known to directly regulate hTERT 
transcription, are shown in boldface type in Table 2, and are 
discussed below. 
 
Table 2:  Tumor Virus Interactions with Transcriptional 
Activators and Repressors of the hTERT promoter. 
* A selection of known regulators of hTERT promoter activity.  
Those viral proteins that have an established role in direct hTERT 
regulation are discussed in the text and shown in bold.  Bmi-1:  
Polycomb-group gene, c-Myc: myelomonocytic leukemia gene, E2F-
1:  E2F transcription factor-1, IRF-1:  IFN-regulatory factor-1, Sp1:  
Specificity protein-1, WT1:  Wilm’s tumor rrotein-1, USF-1/2:  
Upstream stimulatory factor-1/2. BZLF1: (bZIP transactivator of 
EBV), initiates the switch between latent and productive infection in 
B cells (124). vFLIP (viral FLICE inhibitory protein), activates NF-
κB and protects from apoptosis (125). vIRF (viral homolog of the 
interferon regulatory factors), represses interferon antiviral response 
(126). NS4B (nonstructural protein of HCV), part of the replication 
complex of HCV (127). NS5A (nonstructural protein of HCV), aids 
in viral invasion of the immune system and NS3 (nonstructural 
protein of HCV), signals the immune response (128). 
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Impact on 
hTERT
Mode of 
Action
EBV HHV-8 HPV HBV HCV HTLV-I
Bmi-1 Positive - (+) LMP1 - (+) E6 - - -
c-Fos/c-Jun
c-Fos/JunD
Negative Direct (+) LMP1 (+) LANA
(+) vFLIP
(+) E6
(+) E7
(+) X (+) NS4B
(-) NS5A
(+) Tax
c-Myc Positive Direct (+) LMP1 (+) LANA (+) 
E6/E6AP
(+) X (+) Core (+) Tax
E2F-1 Negative
Positive
Sp1
Direct
(+)BZLF1 (+) LANA (+) E7 (+) X (+) Core (+) Tax
IRF-1 Negative - (-) BZLF1 (-) vIRF (-) E7 - (-) -
p16INK4A Negative Sp1 (-) LMP1 (-) (+) (-) (-) (-) Tax
p27KIP1 Negative c-Myc/Sp1 (-) (-) (-) E7 (-) (-) (-)
p53 Negative p21 and 
E2F
(-) (-) vIRF
(-) LANA
(-) E6 (-) X (-) NS5A
(-) NS3
(+)/(-) Core
(-) Tax
p73 Negative c-Myc (-) - (-) E6 - (-) 
p73α/Core
(-) Tax
Smad3 Negative c-Myc (-) LMP1 (-) VIRF1 (-) E7 - (-) Core (-)
Sp1 Positive Direct (+) EBNA2 (+) LANA (+) E6 (+) X (+) Core (+) Tax
Survivin Positive c-Myc/Sp1 (+) LMP1 (+) (+) E6 (+) X (+) NS5A (+) Tax
USF-1/2 Negative
Positive 
Direct - - (-) E6 - - -
WT1 Negative Direct (+)/(-) - - (-) X - (-)  
 
Trans-Activation of the hTERT Promoter by viral oncoproteins  
Most studies of viral transactivation of hTERT gene 
expression have been done with the papillomavirus system, in which 
the HPV E6 oncoprotein has been shown to directly transactivate the 
hTERT promoter.  Mutations in either the GC or the E-box elements 
of the hTERT promoter modestly inhibited telomerase expression, 
demonstrating that independent binding of c-Myc or Sp1 to the 
hTERT promoter is not sufficient for E6-induced telomerase 
activation (73). However, telomerase expression is strongly induced 
by E6 when c-Myc and Sp1 are cooperatively bound to the hTERT 
promoter (73).  Although E6 had no effect on levels of c-Myc gene 
expression, immunoprecipitation studies demonstrated that E6 forms 
a complex with c-Myc on the hTERT promoter (74). The use of 
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E6AP knock-out mice and E6AP siRNA has demonstrated that E6AP 
is important for hTERT promoter activation.  Both E6 and E6AP are 
required for binding to the E-box elements and for the consequential 
activation of hTERT expression (75).  Indeed, a yeast two-hybrid 
screen identified NFX1 as a binding partner of the E6/E6AP 
complex.  NFX1 exists in two isoforms, NFX1-123 and NFX1-91.  
NFX1-123 has been shown to activate the hTERT promoter along 
with c-Myc (39).  
In the case of papillomavirus infection, one possible model 
for the mechanism of hTERT transactivation is that E6 forms a 
tertiary complex with E6AP and c-Myc. Once the complex is bound 
to E-box elements, E6AP could target the degradation of possible 
negative regulators of the hTERT gene, such as NFX1-91 (39) or 
BRCA1 a tumor suppressor that has been found to suppress hTERT 
gene expression by binding to E-box elements (76). In addition, c-
Myc, once activated, may itself be targeted for degradation to limit 
hTERT gene expression. In fact, the E6/E6AP complex has been 
shown to ubiquitinate c-Myc in vitro and in vivo (77). c-Myc has also 
been shown to interact with a transcriptional coactivator, TRRAP, 
that can activate a silent hTERT gene in fibroblasts by inducing 
acetylation of histones H3 and H4 at the hTERT promoter (78).  
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Upstream stimulatory factors -1 and -2 (USFs) have also been 
found to bind to the same E-boxes as c-Myc. USFs can suppress the 
hTERT promoter in nontransformed cells where no hTERT gene 
expression is detected (79). HPV E6 can relieve USF-1 or -2-
mediated repression of telomerase activity by preventing USF-1/ -2 
binding to the hTERT promoter.  This interaction allows for an 
increase in c-Myc binding to the E-box (80).  The exact role of c-
Myc in E6-mediated transactivation of the hTERT gene remains to 
be seen, and additional transcriptional regulators required for HPV-
mediated telomerase activation may remain to be discovered.  
Much less is known about the mechanisms used by other viral 
oncoproteins to transactivate hTERT gene expresssion. The Tax 
protein of HTLV-I is able to stimulate the hTERT promoter through 
activation of the NF-κB pathway.  Chromatin immunoprecipitation 
(ChIP) assays demonstrated increased binding of c-Myc and Sp1 at 
the hTERT promoter in response to NF-κB activation in both HTLV-
I- infected and Tax- expressing cells (60). In fact, a Tax mutant 
unable to activate the NF-κB pathway could not stimulate hTERT 
expression (60).  
The LMP1 protein of EBV has been found to induce c-Myc-
mediated transactivation of the hTERT promoter in primary human 
nasopharyngeal epithelial cells and in a nasopharyngeal carcinoma 
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cell line that stably expresses LMP1 (18). In this case, the C-terminal 
portion of LMP1, which includes CTAR1 and 2 domains, was found 
to stimulate hTERT gene expression through NF-κB activation.   
Lastly, the LANA protein of KSHV has been shown to 
transactivate the hTERT promoter in various cell lines (31).  LANA 
activates hTERT gene expression through interactions with Sp1 (32).   
Most studies on viral-induction/ repression of hTERT 
expression have focused on the core hTERT promoter. This site 
includes the GC and E-box elements that bind Sp1 and c-Myc, 
respectively. However, the distal promoter remains to be explored.  
The region between -2000 and -378 is responsible for JunD and c-
Jun binding to the hTERT promoter. The expression of AP-1, a 
transcription factor that includes Jun and Fos, can lead to hTERT 
promoter repression in some cancer cells (81).  In contrast, activation 
of JNK (c-Jun NH2-terminal kinase) has been shown to increase 
hTERT gene expression (82).  This suggests that hTERT regulation 
could occur by AP1-mediated repression or hTERT activation 
through JNK transactivation.  In HTLV-I and EBV infected cells in 
which both AP1 and JNK pathways are activated (83-86), it seems 
that JNK activation has a dominant effect. 
 
Epigenetic Control of hTERT in virally-infected cells 
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 Activation of hTERT transcription may involve histone 
acetylation, and conversely, repression may involve histone 
deacetylation. Trichostatin A, which inhibits the family of 
mammalian histone deacetylates, activates hTERT gene expression 
in different cell types (87). However, trichostatin A may also activate 
additional genes that directly or indirectly derepress the hTERT gene, 
including c-Myc itself (88). HPV E6 and E6AP expression promote 
acetylation of histone H3, providing epigenic control of the hTERT 
gene (89). Acetylation of histone H3 at the hTERT promoter was 
increased in late passage E6- and E7-immortalized keratinocytes and 
p300 expression was decreased (89). E6 has been shown to target the 
coactivator/acetyl transferase p300 and cells that expressed E6 and 
p300 antisense RNA showed increased acetylation of histone H3 and 
activation of the hTERT gene (89). Therefore, p300 may act as a 
repressor of telomerase activation in the context of E6 expression. 
Other examples of this regulatory mechanism include adenovirus 
E1A binding to p300/CBP and the subsequent recruitment of its 
histone acetyltransferase activity to the hTERT promoter (90). 
 Further control of hTERT gene expression involves histone 
H3 phosphorylation mediated by the mitogen-activated protein 
kinase (MAPK) cascade. In normal human T lymphocytes and 
fibroblasts, growth or stress stimuli that are known to drive H3 
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phosphorylation through MAPK signaling induced hTERT gene 
expression, whereas inhibition of MAPK-triggered H3 
phosphorylation substantially abrogated hTERT induction (91). 
MAPK-mediated control of H3 phosphorylation may have important 
consequences for hTERT gene expression during viral infection 
because c-Jun kinase (JNK) and extracellular signal-regulated 
kinases 1 and 2 (ERK1/2), members of the MAPK family, are 
constitutively activated in HTLV-I-, EBV-, and KSHV- infected cells 
(84,92,93).  
 Finally, the hTERT promoter was more frequently methylated 
in cervical cancer specimens than in normal cervical tissue isolated 
from different patients; however, there was no correlation between 
methylation status and hTERT gene expression (94). A similar 
phenomenon is seen in hTERT-expressing cells, in which a 
demethylated hTERT promoter does not necessarily correlate with an 
increase in hTERT gene expression and both methylation-dependent 
and -independent mechanisms are in place to modulate hTERT gene 
expression (95-97).  
 
Cis-Activation of the hTERT Promoter through viral integration 
In addition to encoding telomerase regulators that act in trans 
on the hTERT promoter, the HPV and HBV genomes have been 
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found in sporadic cases to integrate in proximity to the hTERT gene 
(98-100).  In a subset of cervical and hepatocellular carcinoma 
tumors, the integration resulted in the placement of viral enhancers 
near the hTERT promoter without perturbing the hTERT coding 
region.  Telomerase expression increased in all cases, though it was 
not clear whether the increase was due to viral integration or to the 
action of viral oncoproteins in transformed cells.  Analysis of the 
hepatocellular carcinoma cell line huH-4 produced similar results, 
with HBV integration acting as an enhancer for cis-activation of the 
hTERT gene (101). Many different patterns of karyotypic 
abnormality have been reported in cervical carcinomas, but the most 
recurrent structural chromosomal aberration in cervical cancer is a 
gain of chromosome 3q copy number (102). A recent study 
demonstrated that the gene encoding the RNA component of 
telomerase (hTR) at 3q26 was progressively amplified with the 
development of HPV-associated cervical intraepithelial neoplasias to 
advanced invasive carcinomas (103). This gain of hTR was 
predominantly associated with integration of oncogenic HPV. 
Therefore, it appears that expression of the genes for hTERT 
and/or hTR may be specifically activated by virus integration in a 
population of infected cells.  In concert with other viral proteins, 
enhanced telomerase expression and the resultant increase in 
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telomerase activity could provide a selective advantage by promoting 
transformation.   
 
Post-Transcriptional Regulation of Telomerase Activity 
 Telomerase activity can also be regulated at the post-
transcriptional level.  For example, protein kinase C (PKC) mediated 
phosphorylation of telomerase results in the interaction of telomerase 
and protein hsp90, the latter of which is necessary to maintain the 
integrity of the telomerase holoenzyme (104). Inhibitors of PKC 
substantially reduced telomerase activity present in human 
nasopharyngeal and head and neck cancer cells (104) and PKC has 
been shown to modulate telomerase activity in human cervical cancer 
cells (105), suggesting that EBV and HPV activate PKC to increase 
telomerase enzymatic activity 
Some viruses have evolved mechanisms to exploit the post-
transcriptional regulation of telomerase.  These mechanisms include 
blocking access of the enzyme to its substrate by regulating the 
phosphorylation and nuclear translocation of the hTERT catalytic 
subunit and promoting increased translation of hTERT by regulating 
the poly-A binding proteins that stabilize hTERT messenger RNA 
transcripts. 
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In uninfected cells, AKT has been shown to elevate 
telomerase activity by phosphorylating the hTERT protein, leading to 
its accumulation in the nucleus (106). Similarly, the RelA/p65 
subunit of NF-κB has been shown to directly bind to hTERT and to 
facilitate its translocation to the nucleus (107). On the other hand, 
protein phosphatase 2A (PP2A) has been shown to dephosphorylate 
and inactivate telomerase (108). The LMP1 protein of EBV has 
evolved to exploit this pathway.   In nasopharyngeal carcinoma cells, 
LMP1 can increase telomerase activity post-transcriptionally, by 
promoting NF-κB RelA/p65-mediated binding to and nuclear 
localization of hTERT (109). To date, EBV is the only oncogenic 
virus that has been shown to regulate hTERT nuclear translocation.  
In HPV E6-expressing cells, the E6AP-binding protein 
NFX1-123—in addition to its role as a transcriptional activator of 
hTERT—can also act as a post-transcriptional regulator of hTERT 
(110).  NFX1-123 has been shown to interact with cytoplasmic poly 
(A) binding proteins (PABPCs) affecting RNA stability in the 
nucleus and cytoplasm, and thereby elevating telomerase activity.   
 
Protection of Short Telomeres in Virus-induced Tumor Cells 
 As discussed above, in most tumor cells telomere lengths are 
shortened despite strong telomerase activity. This situation may seem 
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paradoxical; however, several positive and negative regulators of 
telomere length can bind and form a complex, shelterin, that can 
protect or sustain telomere length (10).  Telomerase extension is 
often negated because shelterin blocks access of the telomerase 
reverse transcriptase to the now “closed” ends of telomeric DNA 
(111).   
Three components of the shelterin complex, TRF1 and TRF2 
and, TIN2—are overexpressed in tumor cells of HTLV-I infected 
adult T-cell leukemia/ lymphoma patients (55).  Studies have shown 
that overexpression of either TRF1 or TRF2 results in rapid telomere 
shortening (112).  In addition, TRF1, TRF2, and TIN2 can inhibit 
apoptosis and cell-cycle arrest due to DNA damage (113,114). It is 
possible that the telomeres in adult T-cell leukemia/ lymphoma cells 
reach a critically short length but that the cells are prevented from 
initiating apoptosis and senescence due to the overexpression of key 
members of the shelterin complex. Samples from multiple stages of 
human hepatocarcinogenesis and from patients with non-Hodgkins 
B-cell lymphoma also showed differential expression of shelterin 
components, but whether this was specific to viral infection was not 
elucidated (115).  
A cellular protein, PINX1, has been shown to negatively 
regulate telomerase activity by binding to and inhibiting hTERT 
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directly (116).  However, samples from HTLV-I- and HBV-infected 
patients showed no substantial differences in PINX1 mRNA levels 
compared with uninfected control subjects (55,117).   
 
MECHANISMS OF VIRAL NEGATIVE REGULATION OF 
TELOMERASE 
Telomerase activity is inhibited by cellular differentiation and 
by down-regulation of hTERT transcription; and high levels of 
hTERT are a characteristic of immortalized cells (3).  Several tumor 
suppressor pathways, such as Mad-1/c-Myc or TGF-β, repress 
hTERT in somatic cells, thereby preventing a critical component of 
tumorigenesis from becoming activated (118).   
Thus it may be surprising, then that several oncogenic viruses 
encode negative regulators of telomerase activity. In fact, in addition 
to the positive regulators, there are two known negative regulators of 
hTERT gene expression.  The EBV-encoded transmembrane protein, 
LMP2A, like LMP1, is expressed in the latent stages of disease and 
during cellular transformation. Surprisingly, LMP2A has been shown 
to reduce telomerase expression and activity in epithelial cells by 
repressing hTERT promoter activity through its tyrosine-based 
activation motif (ITAM) (24). Repression of the hTERT gene was 
not associated with changes in cell-cycle progression.  It has been 
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suggested that LMP2A reduces hTERT gene expression to prevent 
B-cell activation and promote the viral latent state (24).  
Reduced activity of E2, an HPV regulatory protein that 
represses E6/E7 expression, is obligatory for HPV-mediated 
carcinogenesis (119,120). In fact, expression of E2 induces 
senescence via pRb- and p21-associated pathways (121) and E2 
represses hTERT gene expression through Sp1 (122). E2 may disrupt 
the interaction of positive-regulators at the hTERT promoter, such as 
the recruitment of histone-deacetylases (HDAC), thereby leading to a 
decrease in telomerase activity. The ability of E2 to repress E6/E7 
and hTERT gene expression may have an important role in the 
induction of senescence.  
NFX1 was identified as a novel telomerase target and as a 
possible candidate for E6/E6AP-mediated telomerase regulation (39). 
The NFX1-91 isoform represses promoter activity in HPV16 E6- or 
c-Myc-expressing keratinocytes by binding to an X-box motif 
adjacent to the E-box (123).   NFX1-91 is also ubiquitinated by the 
E6/E6AP complex.  Why NFX1-123, and not NFX1-91, stimulates 
telomerase expression is still unknown.  Possible explanations 
include the rapid turnover of NFX1-91, the fact that NFX1-91 lacks a 
C-terminal domain similar to that of NFX1-123, or the fact that 
NFX1-91 is expressed predominantly in the nucleus, whereas NFX1-
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123 is mostly cytoplasmic (110). All of these factors may affect the 
binding of NFX1-91 to stimulatory elements at the hTERT promoter. 
Whether NFX1-91 is necessary for the overall regulation of 
telomerase expression during HPV infection and whether additional 
proteins that are required for telomerase transactivation are 
ubiquitinated by E6AP still remains to be demonstrated.  
 Although it may seem counter-intuitive that viruses encode 
negative regulators of telomerase expression, two oncogenic viruses, 
EBV and HPV, have been shown to encode such viral negative 
regulators. In addition, the Tax protein of HTLV-I is a potent 
positive regulator of hTERT expression yet was able to limit hTERT 
gene activation following antigen stimulation. Thus, a balance 
between transcriptional activation and repression of telomerase may 
be important in viruses that require a latent infection. Elevation of 
telomerase expression guarantees that the infected cells can 
proliferate indefinitely in the absence of senescence and apoptosis, 
whereas repression of telomerase may play an important role in 
preventing an immune response against activated infected cells or 
create a state of transient genetic instability.  It would be useful to 
know whether these viral inhibitors are expressed constitutively 
during latency or whether they repress telomerase gene expression 
during a particular stage of disease progression.  
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Conclusions 
 The human tumor viruses have evolved numerous strategies 
to constrain tumor suppressor pathways and to promote cellular 
transformation. Among these, elevation of telomerase transcription 
and/or activity can be used as mechanisms to bypass replicative 
senescence and to increase proliferative capacity, and these 
mechanisms, in turn, increase the cumulative risk of genetic 
alterations. A summary of the data concerning the relationships of six 
human tumor viruses to telomere length and telomerase activity is 
shown in Table 3.  
 
Table 3: 
Telomerase 
Activity
Telomere 
Length
Epigenetic 
Control
Cis-Activation 
of the hTERT 
Promoter
Trans-
Activation of 
the hTERT 
Promoter
Post-
Transcriptional 
Modification of 
hTERT
EBV Elevated Long - - Yes Yes
HHV-8 Elevated - - - Yes -
HPV Elevated Short Yes Yes Yes Yes
HBV Elevated Short - Yes - -
HCV Elevated Short - - - -
HTLV-1 Elevated Short - - Yes Yes
 
Malignant cells infected by all six human tumor viruses studied 
exhibited elevated telomerase activity, yet in all but EBV- infected 
cells, telomere length was found to be shorter than that in uninfected 
control cells.  In the case of EBV, HHV-8/ KSHV, HPV and HTLV-
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I, elevated telomerase activity can be clearly ascribed, at least in part, 
to direct transactivation of the hTERT promoter by viral proteins.  As 
discussed above, the LMP1 protein of EBV, the LANA protein of 
HHV-8/ KSHV, the E6 protein of HPV, the X transactivator of HBV, 
and the Tax transactivator of HTLV-I each can increase transcription 
of the telomerase reverse transcriptase.  Whereas HPV and HBV may 
mediate cis-activation of telomerase transcription, HPV appears to 
enhance its epigenetic activation.  EBV and HPV may regulate 
telomerase post-transcriptionally, by activation of its phosphorylation 
through PKC, promotion of its nuclear translocation through NF-κB, 
or stabilization of hTERT mRNA. However, viral regulation of 
telomerase activity is likely to be complex, and there are indications 
that at some stages of viral infection, some tumor virus proteins can 
also negatively regulate telomerase transcription or activity,  
The diversity of strategies used by tumor viruses underscores 
the complexity of hTERT promoter and telomerase regulation.  
Further investigation in this area is likely to yield many new 
advances and to shed light on potential new therapeutic approaches 
for the treatment of human cancers.  
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Telomerase: A Crucial Player in HTLV-I-induced 
human T-cell leukemia. 
 
 
Abstract: 
 
One in seven human cancers is associated with an oncogenic virus 
infection. Most human tumors have high telomerase activity but very 
short telomeres, yet the maintenance of these short telomeres is 
critical to avoid telomere end fusion or senescence and to support 
active proliferation. Oncogenic viruses have evolved a wide 
repertoire of strategies to stimulate telomerase functions at the 
transcriptional and post-transcriptional levels. Since telomerase 
activity is absent in somatic cells, the inhibition of telomerase is an 
attractive target for cancer therapeutics. 
 
Telomerase and Cancer. 
 
 The “end replication” problem model states that the ends of 
chromosomes cannot be replicated due to the lack of a downstream 
template for DNA polymerase. This eventually leads to a loss of the 
very distal ends of DNA with successive replication cycles, leading 
to telomere attrition, cell cycle arrest, and cellular senescence or 
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apoptosis (1). This normal physiological aging process assures that 
proliferating cells that accumulate genetic defects over time are 
replaced by new undamaged cells and protects against potential pre-
cancerous cells. However, this process needs to be tightly regulated 
because shortened telomeres can also lead to chromosomal instability 
characterized by end-to-end fusions, chromosomal translocations and 
DNA damage responses increasing the risk of cellular transformation 
(2).  
In tumor cells, the existence of a mechanism for the maintenance of 
telomere length is critical and the upregulation of telomerase 
expression and activity has a well established role in carcinogenesis. 
In fact, nearly 90% of all cancers demonstrate an increase in 
telomerase expression (3,4). The remaining 10% of tumors use a 
telomerase-independent alternative lengthening of telomeres (ALT) 
pathway (5).   
Telomerase is composed of hTR, a 451 nucleotide stretch of 
RNA, which serves as a template for the RNA-dependent DNA 
polymerase, telomerase (hTERT).  Through repetitive binding to 
hTR, hTERT is able to lie down tracts of TTAGGG, 10-15 kbp in 
length, which serve to protect and sustain chromosomal ends. 
Telomerase expression alone, however, is not sufficient to sustain 
telomeres, as the shelterin complex, composed of the DNA binding 
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proteins, TRF1, TRF2, and POT1, and their partners, TIN2, hRAP1, 
and PTOP, have been shown to have a definitive role in regulating 
and protecting telomere lengths (6,7). These telomere binding 
proteins prevent recognition of telomere structures by DNA damage 
response proteins, repress recombination mechanisms by altering the 
shape of telomeric DNA, and protect telomeres against the action of 
exonucleases.   
 A proven role for telomerase in the transformation process is 
still ongoing.  The ability of telomerase to avoid cellular senescence 
is evident in early in vitro studies, in which telomerase-negative cells 
and human endothelial cells reconstituted with telomerase, and 
telomerase transduced CD8+ T-cells, were able to prolong growth, 
sustain longer telomeres, and in the case of CD8+ T-cells, maintain a 
normal karyotype, through successive cycles of growth (8-10).  
However, telomerase expression alone may not be enough to induce 
a tumorgenic state in normal cells, as somatic cells expressing 
telomerase are unable to form tumors in nude mice, nor colonies in 
soft agar (11).  Recent studies have shown that forced overexpression 
of hTERT and RasG12V proteins, along with the small and large T-
angtigens of simian virus 40 (SV40), are fully capable of 
transforming human cells.  Transformation could also occur in the 
absence of the viral SV40 proteins, if RB, p53, Ras and c-Myc, are 
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overexpressed, along with hTERT (12).  These findings suggest that 
the overexpression of telomerase can prevent cellular senescence, 
thereby contributing to the transformation process, and once fully 
transformed, can then extend the proliferative capacity of these cells, 
ensuring successive generations of growth.  As the transformation 
process depends upon the deregulation of host cellular proteins and 
pathways, the ability to circumvent these processes is vital to the 
survival of the evading pathogen.  Deregulating host mechanisms is a 
hallmark of all viruses, as they have proven exceptional at perturbing 
host cell homeostasis, and among them, deregulation of telomerase 
activity.   
 
Transformation of ATLL cells by HTLV-I: the case for achieving 
clonal expansion. 
 
Human T-cell leukemia virus type 1 (HTLV-I) is the etiological 
agent of adult T-cell leukemia/lymphoma (ATLL), a 
lymphoproliferative disorder of infected CD4+ T-cells (13).    ATLL 
develops in less than 5% of infected individuals after a long latency 
of 20 to 30 years. The lack of proofreading and subsequent high error 
rates of viral reverse transcriptase (RT) enzymes have been 
associated with the diversity observed in retroviruses. HTLV-I is 
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unusual in that the observed genetic variability among isolates is 
unusually low. Thus, it has been hypothesized that HTLV-I provirus 
replication occurs mainly with the high-fidelity process of cellular 
DNA replication during division of infected cells (14). This concept 
is supported by the fact that treatment with AZT, a reverse 
transcriptase inhibitor, does not reduce proviral loads in infected 
patients over a short period of time. 
  ATLL disease progression is linked to the proviral load, 
which in turn depends on long term survival and proliferation of the 
infected cells. To efficiently achieve clonal expansion, HTLV-I-
infected cells must gain an extended life span while avoiding 
elimination by the host immune responses. Increased longevity may 
in part be explained by an increased expression of anti-apoptotic Bcl-
2 and Bcl-xL in HTLV-I-transformed T-cells in vitro and of Bcl-xL 
in uncultured PBMCs isolated from ATLL patients (15,16).  Escape 
from immune defenses may result from a combinatorial effect of the 
regulatory proteins p30 and p12 that reduces viral expression and 
down-regulate MHC expression, respectively (17,18). Yet to achieve 
clonal expansion, HTLV-I-infected cells must also acquire an 
increased capacity to replicate their DNA and telomeric ends. 
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 HTLV-I infection subverts transcriptional control of the hTERT 
promoter.  
 
 Regulation of the hTERT promoter is complex and subject to 
the positive and negative regulators, c-myc, Sp1, USF1/2, 14-3-3 and 
Mad1, phosphorylated-Rb, PTEN, respectively (19-20).  Regulation 
of the hTERT promoter can also occur by hypermethylation or 
acetlyation (21).  Many oncoviruses have evolved proteins that target 
the hTERT promoter to stimulate telomerase expression and promote 
transformation.  The E6 protein of human papillomavirus (HVP) and 
the LMP1 protein of Epstein-Barr virus (EBV) have been shown to 
transactivate the hTERT promoter (22-24).  HPV E6 was also found 
to promote acetylation of histone H3 and HPV can integrate near the 
hTERT gene (25,26).  Hepatitis B virus (HBV) has also been shown 
to integrate viral DNA into the hTERT promoter, allowing for cis-
activation of telomerase (27).   
 A recent report suggests that the HTLV-I oncoprotein Tax 
may repress transcription from the hTERT promoter and lower 
telomerase activity under specific cell culture conditions (28). Yet, 
such a function of Tax is difficult to reconcile with its capacity to 
immortalize T-cells and other studies showing increased 
transcriptional regulation of the hTERT promoter in HTLV-I and Tax 
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expressing human T-cells. These discrepancies may simply depend 
on the activation status of infected cells. We found that Tax 
suppresses hTERT mRNA expression only when Tax-expressing 
cells are subject to PHA mitogenic stimulation and that in the 
absence of exogenous stimulation, Tax always stimulates expression 
from the hTERT promoter (29). We propose that in response to 
antigen stimulation, interference of Tax with the full induction of 
hTERT expression may result in transient genetic instability during 
mitosis. Once the mitogenic effect has vanished Tax-mediated 
activation of hTERT gene expression offers a long term proliferative 
advantage to these cells that have acquired chromosomal 
abnormalities increasing their chances to repeat this cycle. 
Successive repetition of transient proliferation and stabilization phase 
may be required for the development of ATLL. This model is 
supported by in vitro HTLV-I infection of activated peripheral blood 
mononuclear cells (PBMCs), as PBMCs stimulated by coculture with 
MT2 (HTLV-I producer T-cell line), show a significant decline in 
telomerase activity by week 4, with undetectable levels reached 
during the 5th and 6th weeks of culture.  By week 7, however, 
telomerase activity begins to increase and is significantly elevated by 
week 13.  Telomerase detection by week 7 occurred before the cells 
escaped from crisis, and therefore, is not attributed to a general loss 
 204 
 
of PBMC cells as they died, but rather as a possible mechanism for 
selection and maintenance of transformed cells (29,30).  In addition, 
PBMCs cocultured with MT2 cells produce strong telomerase 
activity that correlates with viral load (29).  Further analysis into this 
model of Tax-mediated hTERT regulation is required in order to 
more fully appreciate the contribution of telomerase in mediating 
transformation of HTLV-I infected T-cells. Real-time PCR analysis 
detected hTERT mRNA expression in all HTLV-I established cell 
lines, IL-2 dependent or independent. Increased expression of hTERT 
mRNA can be detected in PBMCs following coculture with lethally-
irradiated MT2 cells, suggesting that HTLV-I activates endogenous 
hTERT expression (29). Surprisingly, our laboratory found that Tax-
mediated NF-κB activation was responsible for the increased hTERT 
expression. Chromatin immunoprecipitation (ChIP) assays 
demonstrated an increased binding of the transcriptional activators, 
c-Myc and Sp1 onto the hTERT promoter, thereby acting as 
downstream effectors of the NF-κB responses (29). In vivo studies 
also support the idea of HTLV-I-induced telomerase expression, as 
telomerase activity is consistently detected in acute, smoldering and 
chronic ATLL patients (31,32). In fact, disease progression, as 
exemplified from asymptomatic to acute stages of disease, correlates 
with increased telomerase activity, as acute/chronic patients exhibit a 
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higher percentage of telomerase activity than asymptomatic carriers 
(33).  
 
Post-transcriptional regulation of telomerase by HTLV-I Tax 
oncoprotein. 
 
There is abundant evidence that telomerase expression and 
activity is constrained at multiple levels. Several reports have 
identified a lack of correlation between hTERT mRNA levels and 
telomerase activity measured by telomeric repeat amplification 
protocol (TRAP) assays. Although the half life of hTERT mRNA and 
the telomerase complex differ significantly, one and eighteen hours 
respectively, these observations suggest additional post-
transcriptional regulation of the enzymatic activity. The region 
surrounding Ser-824 in hTERT contains a consensus sequence for 
phosphorylation by Akt, and Akt kinase enhances human telomerase 
activity through phosphorylation of hTERT (34). Telomerase must 
be translocated from the cytoplasm to the nucleus in order to act 
upon telomeric DNA. TNF  modulates telomerase activity by 
inducing nuclear translocation of hTERT protein bound to NF- B 
p65/RelA phosphorylated on Ser-536. A specific IKK inhibitor, PS-
1145 that prevent p65/RelA phosphorylation or a specific NF- B 
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nuclear translocation inhibitor, SN-50, both block TNF -induced 
hTERT nuclear translocation and stimulation of telomerase activity 
(35). In addition, EBV’s LMP1 increases telomerase activity in 
nasopharyngeal carcinoma cells post-transcriptionally through NF-
κB mediated phosphorylation and nuclear localization of hTERT 
(36). Finally, 14-3-3 protein can also enhance the nuclear localization 
and activity of hTERT (37).  
 
ATLL cells have short telomeres despite strong telomerase 
activity. 
 
Both HTLV-I immortalized and transformed cell lines and in 
vivo ATLL patient samples have high telomerase activity when 
compared to non-infected PBMCs and asymptomatic carriers.  
However, measurements of telomere lengths show a decrease in size 
in both in vitro and in vivo HTLV-I infected samples, relative to 
normal human T-cells (31,32).  This paradox is not entirely 
surprising, as telomere length does not solely depend upon the 
expression of telomerase and most cancer cells have short telomeres.  
Telomere length is also regulated by several key positive and 
negative regulators that have been discovered of late, which act 
either directly on telomerase or indirectly, by binding to the 
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telomeric DNA itself.  These proteins can then prevent telomerase 
extension by blocking access of the reverse transcriptase to the now 
“closed” ends of telomeric DNA. While the functions of most of 
these telomeric regulators are still being elucidated, it is clear that the 
complex they form (shelterin), can negatively affect the extent of 
telomere elongation by inhibiting the access of telomerase to the ends 
of DNA (38).  In fact, three components of the shelterin complex, 
TTAGGG repeat binding factors, TRF1 and TRF2, and the TRF1-
interacting nuclear protein 2, TIN2, are over-expressed in ATLL 
patients.  Studies have shown that over-expression of either TRF1 or 
TRF2, results in rapid telomere shortening.  In addition, TRF1, 
TRF2, and TIN2 can inhibit apoptosis and cell cycle arrest due to 
DNA damage (39,40).  It is possible that the telomeres of 
transformed ATLL cells reach a critically short length, but the cells 
are prevented from initiating apoptosis and senescence, due to the 
over-expression of key members of the shelterin complex.  Further 
investigations into the roles of these proteins in allowing the 
continuous proliferation of ATLL cells is warranted as it could 
explain how ATLL cells continue to survive, despite short telomeres.          
 
Treatment of ATLLpatients with Telomerase Inhibitors. 
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 The clinical significance of telomerase activity in ATLL 
disease progression can readily be demonstrated upon treatment with 
telomerase inhibitors.  Azidothymidine (3'-azido-3'-deoxythymidine, 
AZT), is a thymidine analog, that has been shown to inhibit cancer 
growth and telomerase activity. AZT is used to treat several virus 
associated human cancers including, AIDS-related Kaposi sarcoma, 
Kaposi sarcoma associated primary effusion lymphoma (PEL), EBV-
associated lymphoma and primary central nervous system lymphoma 
(PCNL). However, until recently the mechanism of AZT action was 
unclear and thus, reasons for treatment failure unknown.  The poor 
prognosis of ATLL patients is associated with the resistance of 
neoplastic cells to the conventional combination of high-dose 
chemotherapy and radiotherapy. Recently, a higher response rate 
following AZT/ IFN alpha treatment of ATLL patients has been 
reported in several human trials (41). Long-term treatment of HTLV-
I infected cells with AZT (or ddG, an additional telomerase inhibitor) 
inhibits telomerase activity, induces telomere attrition, and promotes 
cellular senescence, in absence of apoptosis (42).   HTLV-I infected 
cells undergo senescence during long-term AZT treatment, due to the 
reactivation of tumor suppressor p53 transcriptional activities.  This 
effect is dependent upon telomere shortening.  In vivo patient 
samples of AZT treated ATLL patients show decreases in telomerase 
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activity and telomere lengths.  Further analysis of ATLL patients at 
varying disease stages demonstrates that those patients with a 
transcriptionally functional p53 gene are able to undergo partial or 
complete remission, following AZT/ IFN alpha treatment (43).  
However, those patients with a mutated p53 do not respond to AZT 
treatment and die (44).  These results demonstrate that AZT 
treatment causes telomere attrition that leads to the reactivation of a 
functional p53.   Reactivated p53 is then capable of driving 
senescence in ATLL cells, allowing for patient remission, 
underscoring the importance of telomerase and telomeres in ATLL 
disease status. 
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CONCLUSION: 
 
The aforementioned collection of works establishes 
telomerase as a key component of HTLV-I-mediated cellular 
transformation.  HTLV-I infected cell lines and ATLL patient 
samples display similar telomere dynamics:  an increase in 
telomerase expression and activity, with a shortening of telomere 
lengths.  This pattern is demonstrated in all oncogenic virus 
infections, including those induced by Human papillomavirus (HPV), 
Hepatitis B and C virus (HBV and HCV), and Human Herpesvirus 
8/Kaposi Sarcoma-associated Herpesvirus (HHV-8/KSHV) (Bellon 
M, 2008).  The only exception to this general rule is Epstein-Barr 
virus (EBV), where infection leads to an elongation of telomeres. 
Initial HTLV-I viral infection is associated with an increase in 
telomerase expression, either through transcriptional or post-
transcriptional controls (Figure 9).   
 
Figure 9:  Transcriptional Regulation of hTERT during HTLV-I 
infection. 
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In HTLV-I infected cells, an increase in telomerase 
expression occurs by increased binding of positive telomerase 
regulators, c-Myc and Sp1, to the hTERT promoter through NF-κB 
(132).  Activation of IL-2R signaling pathways, promote PI3K-
mediated retention of the hTERT negative regulator, WT1, from the 
nucleus (Bellon M and Nicot C, Submitted).  In transformed cell 
lines, that are IL-2 independent, Tax may compensate for IL-2R 
signaling, by increasing PI3K activity.  Given the strong activation of 
AP-1 and STAT transcription factors during HTLV-I infection, it is 
likely that additional methods of transcriptional control of hTERT 
during HTLV-I infection still remain to be explored. Though post-
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transcriptional regulation of telomerase was not tested in these 
studies, HTLV-I infected cells display constitutive activation of NF-
κB and elevated AKT activity.  This suggests that post-
transcriptional control of hTERT may play a vital role in elevating 
telomerase activity during disease progression. 
Telomere lengths are progressively shortened in HTLV-I 
infected cells, yet these cells do not undergo cellular senescence or 
apoptosis.  Short telomeres are maintained through increased 
telomerase expression and elevated levels of TRF1, TRF2, and TIN2.  
These shelterin components have been shown to inhibit apoptosis 
and cell cycle arrest due to DNA damage, thereby protecting 
shortened telomeres.  It is still unclear why telomeres initially 
shorten during cancer progression.   It has been suggested that 
shortened telomeres lead to chromosome instability and aneuploidy, 
but this still remains to be proven.  Shortened telomeres are 
prognostic indicators of disease progression in some cancers, 
including hepatocellular carcinoma, chronic myeloid leukemia, and 
chronic lymphocytic leukemia (120).   
Treatment of HTLV-I infected cells with AZT leads to 
telomere shortening and reactivation of p53 transcriptional activities, 
which mediate cellular senescence.    We have shown a direct 
correlation between patient response to AZT therapy and p53 status.  
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We have further demonstrated that p53 reactivation occurs in 
response to DNA damage following telomere attrition, leading to 
ataxia telangiectasia mutated (ATM) kinase activation (135).  ATM 
causes phosphorylation and acetylation of p53, leading to p53 
transcriptional activation of senescence genes.     
Our study with AZT is the first of several reports indicating 
that telomere shortening leads to cellular senescence and reactivation 
of p53 transcriptional activities.  Since our initial description, similar 
mechanisms demonstrating tumor suppression after telomere loss due 
to p53-mediated senescence have also been found (136-138). 
 In our study, treatment of one ATLL patient (ATL4) carrying 
wild-type p53, led to an initial response to AZT treatment, but the 
patient eventually underwent disease relapse.  Proviral integration, 
before and after AZT treatment, demonstrated that during AZT 
treatment, the patient selected for a new clone, which carried a 
transcriptionally inactive p53.  This clearly demonstrates the 
importance of p53 in AZT-mediated therapy and also reveals a limit 
to the use of AZT in treating ATLL:  patients must remain wild-type 
for p53.  Our work demonstrates that AZT/IFN treatment may not 
have success in patients with a mutated p53, and that these patients 
should be treated with conventional ATLL treatments, including 
allogenic bone marrow transplantation, radio immunotherapy for IL-
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2Rα, or chemo- or radio-therapy (139, 140).  We have also 
demonstrated in vitro success with Arsenic trioxide/interferon-α 
(ATO) in combination with emodin and docosahexaenoic acid 
(DHA) (141).  The combination of these drugs leads to cell-cycle 
arrest and cell death of HTLV-I infected cells.  The importance of 
ASO treatment is shown by the fact that AZT treatment, or any anti-
hTERT therapy, is p53-dependent, whereas ASO treatment is p53-
independent.  Clinical trials of ASO in combination with DHA and 
emodin remain, in order to determine the efficacy of this treatment in 
ATLL patients.   
Analysis of p53 status at the on start of treatment could be 
highly beneficial to disease outcome, as most patients that undergo 
chemotherapy or radiotherapy select for tumor clones that carry 
mutant p53 (142).  Instead, patients with wild-type p53 should be 
placed on AZT/IFN as a first line of therapy.   ATLL patients have 
demonstrated a complete response and suppression of HTLV-I while 
undergoing alemtuzumab therapy, a monoclonal antibody targeted to 
CD52 that is present on mature lymphocytes.  It is possible that 
alemtuzumab could be used in conjunction with AZT, to prevent 
emergence of mutated p53 clones (143).   
 
Future Directions: 
 223 
 
We have extensively studied the core promoter of hTERT.  
We have found that in HTLV-I infected cells, there is increased 
binding of c-Myc and Sp1, two positive regulators, and decreased 
binding of WT1, a negative regulator of hTERT expression.   
However, the distal promoter of hTERT still remains to be studied in 
the context of HTLV-I infection.  Studies have shown that the AP-1 
family of transcription factors, which include c-fos/c-Jun and c-
fos/JunD can bind to the distal hTERT promoter between -2000 and -
378 of the transcriptional start site.  The c-Jun NH –terminal kinase 
(JNK) increases hTERT expression, whereas AP-1 can repress the 
hTERT promoter.  AP1 and JNK pathways are both activated in 
HTLV-I infected cells.    In vitro biotin pull down assays or 
chromatin-histone immunoprecipitation assays (CHIP), using AP-1 
transcription factors, would demonstrate whether there was an 
increase or decrease in these factors bound to the hTERT promoter in 
HTLV-I infected cells.   Transient transfection assays in HTLV-I 
infected cells, with an hTERT luciferase construct and varying 
concentrations of AP-1 transcription factors, would aid in 
establishing whether these factors are positive or negative regulators 
of hTERT transcription in HTLV-I infected cells.  In addition, 
inhibition of JNK or MAPK pathways with pharmacological 
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inhibitors, would give a view of the pathways involved in hTERT 
regulation in HTLV-I infected cells. 
  We have found that the distal hTERT promoter also contains 
a putative binding site for signal transducer and activator of 
transcription (STATs) transcription factors.  HTLV-I infected cells in 
vitro and in vivo have constitutive activation of JAK/STAT 
pathways.   Biotin pull-down assays with the hTERT promoter or 
CHIP analysis using STAT antibodies,  and treatment with JAK 
inhibitors, would demonstrate whether there is an increase or 
decrease in these transcription factors in HTLV-I infected cells 
compared to normal PBMCs.  In addition, mutation of the putative 
STAT binding site, within the hTERT luciferase promoter, would 
demonstrate the importance of the JAK/STAT pathway in promoting 
hTERT expression. 
 Using AKT inhibitors, we have shown that AKT acts as a 
potent post-transcriptional regulator of hTERT activity.  However, 
our data has primarily focused on transcriptional regulation of 
hTERT expression.  Further analysis into hTERT post-transcriptional 
regulation in HTLV-I infected cells would aid in understanding the 
role of telomerase in HTLV-I infected cells.  Protein kinase C (PKC) 
phosphorylates hTERT and aids in holoenzyme integrity.  PKC has 
been shown to modulate hTERT activity in cervical cancer cells, as 
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well as human nasopharyngeal and head and neck cancer cells.  
Given that PI3K is a strong regulator of hTERT activity in HTLV-I 
infected cells, and PKC lies downstream of PI3K, it is possible that 
PKC positively impacts hTERT during HTLV-I infection.  Long-
term inhibition of PKC, with pharmacological inhibitors, would 
demonstrate a role for PKC in post-trancriptionally regulating 
hTERT in HTLV-I infected cells.    The RelA/p65 subunit of NF-κB 
can bind hTERT and aid in the nuclear localization of hTERT.  
While removal of IL-2, in HTLV-I infected cells, showed no short-
term (4 hours) effects on NF-κB localization, demonstrated that NF-
κB was not primarily involved in IL-2 regulation of hTERT 
transcriptional activation; it does have a role in regulating c-Myc and 
Sp1 activity on the hTERT promoter in HTLV-I infected cells.  
Treatment with NF-κB inhibitors, or inhibition of NF-κB nuclear 
localization, would demonstrate whether NF-κB plays a role in post-
transcriptionally regulating hTERT in HTLV-I infected cells.   Tax, 
like the LMP1 protein of EBV, may promote NF-κB RelA/p65-
mediated binding to and nuclear localization of hTERT.  
 An area of hTERT regulation that has not been studied in-
depth is epigenetic control  of hTERT activity.  Hyper-methylation of 
the promoter of genes often leads to a reduction in transcription of 
the gene.  In contrast, hypo-acetylation of the promoter, leads to gene 
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activation.  HPV proteins, E6 and E6AP, have been shown to 
promote acetylation of histone H3 of the hTERT promoter and 
adenoovirus  E1A protein binds to p300/CBP to recruit histone 
acetyltransferases to the hTERT promoter.  In addition, histone H3 
phosphorylation by MAPK, leads to hTERT expression.  JNK and 
ERK1/2, transcriptional factors activated by MAPK, are 
constitutively activated in HTLV-I infected cells.  Treatment with 
trichostatin A, which inhibits histone deacetlyases, and subsequent 
analysis of hTERT activity, would demonstrate a role for epigenetic 
regulation of hTERT in HTLV-I infected cells.  Epigenetic regulation 
of hTERT expression through methylation of the hTERT promoter is 
complicated, as, in contrast to the general pattern of gene regulation, 
methylation status does not correlate with hTERT gene expression.   
Treatment of HTLV-I infected cells with bisulfate (which leads to 
conversion of unmethylated cytosines to uracils, whereas methylated 
cytosines are unchanged), along with methylation-specfic PCR, 
would demonstrate whether the hTERT promoter is methylated or 
unmethylated.  Further treatment with 5-azacytodine, which inhibits 
methylation, in HTLV-I infected cells, followed by TRAP analysis of 
telomerase activity, would aid in understanding whether methylation 
plays a role in hTERT regulation.  However, it does not demonstrate 
a direct effect of promoter methylation on hTERT expression, as 
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treatment with 5-azacytodine, could effect the expression of known 
positive and/or negative transcriptional or post-transcriptional 
regulator of hTERT expression, therefore, having an indirect effect.  
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